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ABSTRACT 
The overall goal of this thesis is to develop a better understanding of the brain’s regulation of 
appetite, i.e. the hypothalamic regulation of hunger and satiety signals. The correct regulation 
of appetite is crucial, potentially involved both in traditional eating disorders, such as anorexia 
nervosa and bulimia nervosa, as well as overweight, obesity and failure to thrive in infants and 
children. Anorexia/cachexia is also a severe and frequent complication to several common 
disorders such as cancer, HIV, renal failure and Alzheimer’s disease and is one of the most 
important factors determining both quality of life and mortality in these conditions.  
In this thesis, the anx/anx mouse is used as a tool to develop a better understanding of the 
hypothalamic regulation of food intake in an anorectic condition. Previous studies on the 
anx/anx mouse hypothalamus showed several abnormalities in the expression of 
neurotransmitters and neuropeptides in the orexigenic NPY/AgRP and the anorexigenic 
POMC/CART system. In order to elucidate when this abnormal phenotype first appears, we 
studied the development of the NPY/AgRP system in Paper I. The development of the 
NPY/AgRP system in the anx/anx mice is normal until P12. From this day, a gradual decrease 
in fiber density is seen with the weakest expression at P21, results that clearly show an impaired 
development of the NPY/AgRP system in the anx/anx mouse. A second aim for Paper I was 
to study the underlying mechanisms for this impaired development. We therefore analyzed the 
expression of markers of activated microglia and detected a gradual increase in these markers 
in the same areas and at the same time points as was seen for the gradual decrease in density of 
AgRP fibers. The impaired development of the AgRP system and the overlapping activation 
of microglia in the hypothalamus of the anx/anx mouse indicate an inflammatory/degenerative 
process. This was further investigated in Paper II, where we detected expression of MHC class 
I mRNA and protein in the arcuate nucleus, both in glial cells and in neurons. We also found 
that the neurons expressing the MHC class I subunit are ‘silenced’ or have a very low activity. 
Further evidence for neurodegeneration was seen in Paper II, as we detected a significantly 
increased number of apoptotic cells in several hypothalamic areas of the anx/anx mouse, as 
well as a double-labeling of NPY and active caspase 6, a marker for axonal degeneration, in 
neuronal fibers. Altogether, these results point to a neurodegenerative process in the 
hypothalamus of the anx/anx mouse. In Paper III, we continued the search for the anx 
gene/mutation to find the causes leading to the anorectic phenotype. Through a microarray 
study and the following pathway analysis the first indications were given that the anorectic 
phenotype in the anx/anx mouse is related to mitochondrial dysfunction and oxidative stress. 
We also detected that the anx mutation leads to decreased expression of the Ndufaf1 gene and 
protein. This gene, located within the anx interval, encodes an assembly factor for 
mitochondrial complex I. We show that the downregulation of Ndufaf1 is associated with the 
anx-allele and not due to a secondary effect of the starvation. We could also see that the 
downregulation of the Ndufaf1 gene leads to a less completely assembled mitochondrial 
complex I and the accumulation of sub-complexes, as well as increased levels of reactive 
oxygen species, in the anx/anx hypothalamus. Based on these results, we concluded that the 
anorexia and premature death of the anx/anx mouse is related to mitochondrial dysfunction and 
oxidative stress. In Paper V, we evaluated whether the activity in the hypothalamus is 
attenuated in the anx/anx mouse as a consequence of the defect mitochondrial complex I. We 
could see that hypothalamic glucose uptake in the fasted state was reduced in the anx/anx 
mouse. Further, the anx/anx hypothalamus had elevated levels of one of the glucose 
transporters, GLUT4 and a key metabolic molecule, AMPK. However, the hypothalamic 
activation state of AMPK was significantly decreased. Finally, during metabolic stress, levels 
of both AMP and IMP (both breakdown products of ATP) were decreased, while ATP levels 
were increased in the anx/anx hypothalamus. Together these results indicate that the anx/anx 
mouse has a reduced hypothalamic metabolism. This may contribute to the anorectic behavior 
of this mouse i.e. its inability to regulate food intake in response to the energy status. In Paper 
IV, we evaluated whether the inflammation and the mitochondrial dysfunction in the 
hypothalamus of the anx/anx mouse also could be detected in the endocrine pancreas, and if 
glucose homeostasis is disturbed. We found a strong downregulation of the Ndufaf1 gene, 
paralleled by a reduced mitochondrial complex I activity in isolated anx/anx islets. In addition, 
there was an increased macrophage infiltration in anx/anx islets, indicating inflammation. 
Moreover, elevated levels of free fatty acids were seen in anx/anx serum. In contrast, isolated 
islets from anx/anx mice cultured in the absence of free fatty acids did not show any 
inflammation. Also, an intraperitoneal injection of glucose to the anx/anx mouse revealed a 
marked glucose intolerance associated with reduced insulin release. However, the insulin 
release from isolated anx/anx islets was increased after stimulation either with glucose or KCl. 
The conclusion of Paper IV is that the anx/anx endocrine pancreas display marked reduction 
in insulin release that correlates with the increased serum levels of free fatty acids, and that the 
accompanying in vivo inflammation may lead to inhibition of insulin secretion. 
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1 BACKGROUND 
1.1 EATING DISORDERS 
A functional energy homeostasis, that is an accurate regulation of the balance between energy 
intake and energy expenditure, is essential from several points of view. In fact, a dysfunctional 
regulation of energy homeostasis is a severe complication associated with many common 
diseases. One way to disrupt energy balance is a disturbed appetite, resulting in excessive or 
severely reduced food intake. This can lead to overweight and obesity or eating disorders, such 
as anorexia nervosa (AN) or bulimia nervosa (BN). In turn, overweight and obesity increase 
the risk for type 2 diabetes (T2D), cardiovascular disorders [1], and certain types of cancers, 
e.g. colon cancer [2]. On the other hand, anorexia, meaning poor appetite, is not just a term 
referred to the severe eating disorder AN, but is also a frequent complication of many somatic 
diseases such as cancer, HIV, renal failure, inflammatory disorders, chronic kidney disease, 
chronic heart failure, and Alzheimer’s disease [3-5]. This severe state of malnutrition, called 
cachexia, is a condition of nutrient imbalance in combination with an already severe disease, 
and is a consequence of a decreased appetite combined with an increased energy expenditure 
[6]. In this situation, when the body is already struggling against a disease, the severity of 
cachexia is one important factor determining both quality of life and mortality. In fact, in AIDS 
patients retaining body mass retention has the strongest association with survival [7, 8]. 
Another anorectic condition is called failure to thrive (FTT), also known as weight faltering. 
That is a term used to describe a young child or infant with insufficient weight gain in relation 
to its age and gender, and is caused by undernutrition in relation to this child’s specific energy 
requirements [9, 10]. Non-organic FTT is when faltering growth is seen, and no organic causes 
are found. These children fail to grow, because they consume insufficient calories, most of the 
time due to a decreased appetite, resulting in decreased caloric intake. It appears as if the 
hypothalamus, seen as the appetite center of the brain, is not in tune with the calorie 
requirement of the child [11, 12].  
Another class of diseases with a primary alteration in the mechanisms controlling appetite and 
body weight are the eating disorders already mentioned, the most well known ones being AN 
and BN. Dieting and weight control are strongly associated with the onset of eating disorders. 
In fact, body dissatisfaction is the best-known contributor to the development of eating 
disorders [13]. Several studies show an increase of body dissatisfaction mostly among young 
women and children [14-16]. Most of the persons dieting will regain their weight within a few 
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years; however, studies have shown that 35% of persons dieting will continue to a pathological 
dieting and of those 20-25% will develop an eating disorder [17]. 
Another group of individuals showing an increased risk of developing an eating disorder is 
individuals with type 1 diabetes (T1D) [18, 19]. Some individuals with diabetes intentionally 
reduce or omit insulin to control weight. This manipulation of insulin coupled with eating 
disorders behaviors is termed diabulimia [20]. The numbers vary, but studies show a range 
between 30-40% of individuals with T1D who also develop unhealthy weight controls, such as 
manipulating weight with insulin, or meet the criteria for an eating disorder [21]. This is an 
unhealthy combination that results in poor metabolic control. The individual not only struggle 
with the complications due to the eating disorder, but also eventually develops diabetes-related 
complications.  
AN is a serious form of eating disorder characterized by self-starvation leading to an excessive 
weight loss. This is also combined with a strong fear of gaining weight as well as an inability 
to understand the severity of the situation (DSM-V). During the progress of AN, the body does 
not, for a longer period, receive sufficient nutrients, resulting in a weakened body and an 
inability of the body to function normally. There are severe consequences of this, since the 
body is forced to slow down all its necessary processes to save energy, resulting in e.g. slow 
heart rate, low blood pressure and muscle loss [22]. In addition, among individuals suffering 
from an eating disorder there is an increased risk for depression [23, 24], and AN has the highest 
death rates of all psychiatric disorders with a mortality rate as high as 10% [25-29].  
As for today, the causes for AN are to a large extent not known. We do know that additive 
genetic factors account for 50-80% of the background [3, 28], but we still lack knowledge of 
which these genetic variants are.  A genome wide association study (GWAS) recently reported 
the first genome-wide significant locus for AN at a site previously implicated in T1D 
(http://dx.doi.org/10.1101/088815). They also report significant negative SNP-based genetic 
correlations between AN and body mass index (BMI) and cardiometabolic parameters. Three 
genetic loci involved in both AN and BMI was also detected in another study [30]. These 
findings suggest that AN should be seen as a disorder not only with psychiatric but also 
metabolic components. However, due to lack of knowledge about, in particular, the molecular 
neurobiological pathways involved in the development and progress of AN, we face a situation 
where the best treatment methods still need to be found. The most important factor for full 
recovery from AN is early treatment. The probability of a full recovery from AN depends on 
the duration of the condition [25-29]. This underlines the need to further study and better 
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understand the mechanisms underlying appetite control and to find new methods for treatment 
to obtain full recovery from different kinds of eating disorders.  
This thesis is based on the anorectic anx/anx mouse (to be described fully in a separate section 
below), a unique, genetic mouse model for studying appetite control and disturbed feeding 
behavior. The anx/anx mouse shows similar phenotypes with several conditions of 
dysregulated appetite such as AN [4], cachexia [8] and FTT [31]. Studying this model may 
thus give us new insights into severe eating conditions, including a dysregulated appetite, and 
may lead us to new and better methods for the treatment of this conditions.  
1.2 HYPOTHALAMIC REGULATION OF FOOD INTAKE 
Hypothalamus is the site for several neuronal networks regulating appetite and body weight, 
i.e. the control of initiation and termination of food intake. This is also the place for regulation 
of glucose and energy homeostasis [32-49]. These networks can directly sense metabolic 
information from the periphery and then convert this information to metabolic signals of hunger 
or satiety [50].  
In the arcuate nucleus (Arc) of the hypothalamus, two groups of neurons are located with 
opposite effects on feeding, e.g. hunger and satiety signaling neurons [51]. The satiety signaling 
group of neurons express two anorexigenic peptides, pro-opiomelanocortin (POMC) and 
cocaine-amphetamine-regulated transcript (CART) [52-55]. The POMC precursor is cleaved 
into α-melanocyte-stimulating hormone (α-MSH) which, upon stimulation, reduces food intake 
and increases energy expenditure [56, 57]. The hunger signaling group of neurons co-expresses 
two orexigenic neuropeptides, neuropeptide Y (NPY) [58-60] and agouti related neuropeptide 
(AgRP) [61-65] which stimulate food intake and reduce energy expenditure upon activation 
[66, 67].  
Both the anorexigenic and the orexigenic groups of neurons are regulated by circulating 
metabolic hormones such as leptin, insulin, and ghrelin which bind to their corresponding 
receptors to transmit their specific response of hunger or satiety [68-70]. Insulin, produced by 
the β-cells, and leptin, secreted by adipocytes, circulate at levels proportional to body fat and 
enter the brain in proportion to their plasma levels. Both insulin and leptin act as anorexigenic 
hormones by stimulating POMC/CART neurons and inhibiting AgRP/NPY neurons, resulting 
in decreased food intake [71]. Ghrelin is a protein secreted from the stomach and is released 
during fasting. It activates the orexigenic AgRP/NPY neurons in the Arc, thereby stimulating 
food intake [72-74] (Fig. 1).  
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Both the POMC/CART and AgRP/NPY neurons project further to other hypothalamic areas, 
such as ventromedial hypothalamus (VMH), dorsomedial hypothalamus (DMH), the 
paraventricular nucleus (PVN) and the lateral hypothalamic area (LHA) as well as brain regions 
outside of the hypothalamus, such as the bed nucleus of the stria terminalis (BNST) [39, 75-
81].  
Melanocortin receptor 4 (MC4-R) is found in neurons in the PVN [82] and decreases food 
intake and increases energy expenditure upon activation. MC4-R is activated by high levels of 
α-MSH, and by decreased levels of NPY, and of AgRP that works as an antagonist at the MC4-
R [83, 84]. High levels of insulin and leptin activate POMC/CART and suppress NPY/AgRP, 
resulting in increased activity of MC4-R. Activated MC4-R results in suppressed activity of 
AMP-activated protein kinase (AMPK), a sensor of energy depletion that upon activation 
increases appetite, and thereby leads to decreased food intake and increased energy expenditure 
[84].   
 
Fig. 1 Schematic overview of the regulation of food intake via peripheral metabolic signals, such as leptin, insulin and ghrelin, 
to the arcuate neurons NPY/AgRP and POMC/CART. Insulin and leptin inhibit AgRP/NPY neurons and stimulate 
POMC/CART neurons. Ghrelin can activate AgRP/NPY neurons and thereby stimulate food intake. AgRP/NPY neurons 
stimulate food intake and decrease energy expenditure and POMC/CART neurons inhibit food intake and increase energy 
expenditure. Ghsr, growth hormone secretagogue receptor; Lepr, leptin receptor; Mc3r/Mc4r, melanocortin 3/4 receptor; Y1r, 
neuropeptide Y1 receptor. Image modified from [85] 
  5 
1.2.1 Hypothalamic AMPK – a regulator of energy homeostasis 
AMPK is a sensor and regulator of energy homeostasis and protects the body against energy 
depletion by stimulating appetite when activated, i.e. AMPK is activated during starvation and 
inactivated during feeding [86, 87]. AMPK exerts its actions by stimulating the orexigenic 
neuropeptides and inhibiting the anorexigenic neuropeptides, leading to increased food intake. 
The activation of AMPK also results in reduced thermogenesis aiming at decreasing energy 
expenditure [84, 88].  
The activation or inhibition of AMPK is regulated by several different factors e.g. the metabolic 
hormones insulin, leptin and ghrelin. Insulin and leptin are both inhibitors of AMPK, since 
both insulin and leptin levels increase after food intake [89, 90]. Insulin can reduce the activity 
of AMPK in all hypothalamic regions, whereas leptin inhibits AMPK activity in the Arc and 
PVN [84]. Ghrelin is an activator of AMPK, and increases appetite by the activation of AMPK 
in both VMH [91] and in Arc [92] via growth hormone secretagogue receptor type 1 (GHS-
R1) [93, 94].  
Another AMPK regulator is adenosine triphosphate (ATP). Low levels of ATP reflect a low 
total energy reserve. AMPK is activated in response to ATP depletion, which causes an 
increase in the adenosine monophosphate (AMP):ATP or adenosine diphosphate (ADP):ATP 
ratios [95-97]. Activation of AMPK promotes the production of ATP by stimulating catabolic 
[98, 99] and inhibiting anabolic processes requiring ATP [100-103].  
AMPK can also sense the levels of glucose and thereby regulate glucose homeostasis. The 
activation of hypothalamic AMPK results in increased glucose production, and AMPK can 
thereby protect the brain against hypoglycemia. This is an important task for AMPK, since 
glucose is the main source of energy for the body and is important for normal brain activity. In 
fact, if blood glucose drops below normal levels, this will result in hypoglycemia, a condition 
that can lead to instability and abnormal function of the brain [104-108].  
Finally, another stimulator of AMPK is through contraction of the skeletal muscles. Thus, 
intense exercise significantly increases AMPK activity in humans [109].  
1.3 NEUROINFLAMMATION 
Microglia are the immune cells of the brain with a protective role to seek and destroy pathogens 
and to clear the tissue from cellular debris. When microglia are in a resting state, they have a 
ramified appearance with long processes extended from the cell body. Microglia use these 
processes to ‘search’ the surrounding environment to identify pathogens [110, 111]. The resting 
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microglia have a low expression of major histocompatibility complex (MHC) proteins [112]. 
When detecting pathological changes, brain injury and damaged or dead cells, microglia 
become activated and change their morphology into an amoeboid shape [113]. The activated 
microglia migrate to the site of the injury, where they phagocytose and destroy pathogens and 
remove damaged or dead cells. As a part of this response activated microglia release pro-
inflammatory molecules, e.g. cytokines and chemokines, which help to elevate and direct the 
immune response, as well as cytotoxic factors, e.g. tumor necrosis factor-α (TNF-α), nitric 
oxide (NO) and reactive oxygen species (ROS), with the aim to destroy the pathogens [114-
116]. However, microglia can also become neurotoxic by being chronically activated. If that 
happens, they become a chronic source of cytokines and ROS that will result in progressive 
neuron damage. This state of chronic and neurotoxic microglia activation has been implicated 
in the pathology of several neurodegenerative diseases [117]. 
The activation of microglia also results in increased expression of MHC molecules, giving 
microglia an antigen-presenting capacity.  MHC Class I and II are cell surface glycoproteins 
that bind and present antigens to T lymphocytes [118]. MHC proteins can be expressed by both 
neurons and glial cells. Neurons express MHC Class I protein during acute inflammation and 
following changes in electrical activity [119-122], and glial cells express MHC class I and/or 
II during pathological conditions, e.g. multiple sclerosis and brain injury [123, 124].  
1.3.1 Hypothalamic inflammation in relation to food intake  
Hypothalamic inflammation can induce dysfunction in energy homeostasis and promote both 
obesity and anorexia. Low-grade inflammation in the hypothalamus suppresses the signals 
from insulin and leptin, leading to insulin and leptin resistance as well as increased food intake 
and decreased energy expenditure that promotes obesity. Several studies show a connection 
between hypothalamic low-grade inflammation and obesity [125-127]. However, a high-grade 
inflammation in hypothalamus results in decreased food intake and increased energy 
expenditure. Hypothalamic high-grade inflammation induces anorexia, and can result in the 
cachexia occurring in, e.g. cancer. It is the same inflammatory mechanisms that can induce 
both obesity and anorexia depending on the level of inflammation; however, the exact threshold 
when the condition of obesity changes to a condition of anorexia is not known [128]. There are 
indications that microglia may play a direct role in the regulation of food intake [129]. Thus, 
microglia activation in the brain is involved in both anorexia and body weight loss, as well as 
in the development of obesity.  
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1.3.1.1 Hypothalamic inflammation and microglia activation in obesity and anorexia 
The accumulation of activated microglia in the hypothalamus has been linked to the 
development of obesity. Hypothalamic microglia are thought to be sensors of saturated fat, 
since they are shown to be activated by increased levels of free fatty acids (FFAs). During these 
conditions, e.g. the activation of microglia in the hypothalamus due to high intake of saturated 
fat, the activated microglia could be responsible for changes in hypothalamic functions, such 
as a decreased hypothalamic sensitivity to leptin, resulting in increased food intake. Several 
studies using animal models, where obesity is induced by high-fat diet (HFD), show this 
connection. In these animal models HFD induces inflammation and triggers the activation and 
accumulation of microglia in neurons in the Arc [130-132]. It is thought that the inflammation 
and microglia activation could be the cause of the neuronal injury and apoptosis seen in 
hypothalamic nuclei, both in rodents fed with HFD and in neurons treated with fatty acids [133, 
134]. The activation of microglia cells and the neuronal injury results in dysfunction of 
hypothalamic neurons regulating food intake and energy homeostasis, that in turn can promote 
obesity [135]. 
Hypothalamic inflammation and microglia activation has also been linked to anorectic 
conditions. One study shows that anorexia and body weight loss developed as a result of 
activated microglia in the Arc. In an animal model, hypothalamic inflammation was triggered 
through the activation of toll-like receptor 2 (TLR2). This resulted in activation and 
accumulation of microglia in the Arc, and increased activity of POMC neurons, leading to an 
anorectic behavior in these mice [136].  
In addition, the anorexia-cachexia syndrome has been associated with several pro-
inflammatory cytokines released during inflammation, such as tumor necrosis factor (TNF) 
and interleukin 1β (IL-1β). These cytokines can be produced by neurons or glial cells in the 
CNS and can alter the function of several appetite regulating neurons in the Arc and, in this 
way, control the energy regulation in this syndrome [137-141]. This is also seen in animal 
models, where the anorexia-cachexia syndrome develops through administration of cytokines 
[142-146], and the symptoms of this condition are inhibited with the help of  anti-TNF 
antibodies [145, 147, 148].  
Furthermore, several approaches with the aim to inhibit the overall inflammation result in 
decreased hypothalamic inflammation and increased food intake in animal models of anorexia. 
To take a few examples, hypothalamic inhibition of AMPK reduced the hypothalamic 
inflammation and increased food intake in cancer-induced anorexia [149]. Also, in tumor-
bearing rats it was shown that the hypothalamic inflammation was suppressed after physical 
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exercise [150]. And lastly, it was seen that the expression of IL1-β was reduced after ghrelin 
treatment, and this resulted in increased food intake [151, 152].  
1.4 THE MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION SYSTEM 
The mitochondrial oxidative phosphorylation system (OXPHOS), located in the mitochondrial 
inner membrane, is responsible for production of energy, i.e. the ATP required for the cells. 
This system consists of five complexes (CI-CV) and two electron carriers, ubiquinone (Q) and 
cytochrome c (cyt c). The first four OXPHOS complexes (CI-CIV) together with the two 
electron carriers, build up the electron transport chain and transfer electrons from the substrates 
nicotinamide adenine dinucleotide (NADH) (at CI) and flavin adenine dinucleotide (FADH2) 
(at CII) through the chain to the final electron acceptor, molecular oxygen at CIV. The energy 
generated by this electron transfer is used to build up a gradient by protons being transferred 
across the mitochondrial inner membrane at CI, CIII, and CIV. The proton translocation results 
in a mitochondrial membrane potential that is used by complex V to generate ATP from ADP 
and inorganic phosphate (Fig. 2) [153].  
1.4.1 Mitochondrial ROS production in the OXPHOS system 
Mitochondrial ROS, e.g. superoxide (O2-) and hydrogen peroxide (H2O2), are generated during 
the mitochondrial OXPHOS process. During normal conditions, the final electron acceptor at 
CIV, i.e. the oxygen molecule, is reduced to produce water. However, leakage of electrons, 
mainly from CI and CIII, leads to incomplete reduction of oxygen, to form superoxide, the 
precursor of most other ROS. The cell has an antioxidant defense system that can convert the 
different forms of ROS to less reactive forms and to water. Superoxide dismutases (SOD), 
glutathione peroxidases (GPX), and peroxiredoxins (PRDX) are all compounds belonging to 
the cells antioxidant defense system. There are three different isoforms of SOD localized in 
different places in the cell: copper-zinc SOD (CuZn-SOD or SOD1) localized in the 
mitochondrial intermembrane space and the cytosol [154], manganese SOD (Mn-SOD or 
SOD2) localized in the mitochondrial matrix, and an extracellular CuZn-SOD (EC-SOD or 
SOD3). Genetic elimination of Mn-SOD, in contrast to the other isoforms, is embryonically 
lethal [155, 156]. Thus, after the production of superoxide, the cell uses its antioxidant defense 
system to convert superoxide to hydrogen peroxide by the different isoforms of SOD. In the 
mitochondrial matrix, hydrogen peroxide is further detoxified by being fully reduced to water 
by, GPX1, PRDX3 or PRDX5 (Fig. 2) [157]. 
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Fig. 2 Schematic drawing of the mitochondrial oxidative phosphorylation system. Five complexes (CI-CV) in the mitochondrial 
inner membrane, together represent the OXPHOS system. NADH is oxidized by complex I and FADH2 by CII, thereby releasing 
electrons that are transferred via electron carriers [ubiquinone (Q) and cytochrome c (CytC)] as well as complexes III and IV 
to the final acceptor, molecular oxygen. When electrons are transferred along the protein complexes, protons are pumped out 
through CI, CIII and CIV. The protons flow back through CV and drive the ATP-synthesis. Leakage of electrons from CI and 
CIII leads to production of O2-, that is released in the matrix and intermembrane space. O2- is also diffused via VDAC to the 
cytosol. Mn-SOD in the matrix and CuZn-SOD in the intermembrane space and the cytosol degrade O2- to H2O2. In the matrix 
H2O2 is further detoxified to water by GPX. Image modified from [157]. 
1.4.2 Oxidative stress and apoptosis 
The role of the cells antioxidant systems are to protect the organism from excessive levels of 
ROS, i.e. oxidative stress, a condition when the production of ROS and the ability of the cell 
to defend against ROS are not in balance. Both the production and the detoxification of ROS 
can be disturbed [158, 159]. The production of ROS is disturbed, for example by defect 
mitochondria, since they release large amounts of ROS. The detoxification of ROS is 
attenuated in response to decreased antioxidative enzyme activities [160]. During this condition 
the levels of ROS increase to amounts that the cells cannot handle, and ROS becomes toxic to 
the cell. This condition, i.e. oxidative stress, contributes to several pathological states, such as 
inflammation, diabetes mellitus, tumor formation, mental disorders such as depression, and 
neurodegenerative disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) 
[161-164]. ROS are considered a key factor in neurodegeneration by causing oxidative stress 
and cell death [165, 166]. However, ROS do not only cause oxidative stress but can also, at 
moderate levels, function as signaling molecules and directly control many brain functions. 
Neurons can sense, transmit and convert ROS signals into appropriate intracellular responses. 
In this way, ROS function as a food intake-regulating signaling molecule in the hypothalamus 
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affecting the Arc neurons and thereby regulate food intake and metabolism in response to 
metabolic signals. Increased levels of ROS inhibit food intake [167-169]. 
1.4.3 Complex I deficiency  
CI is considered the main producer of ROS both during normal conditions, as a by-product of 
cellular metabolism, and during pathological processes such as neurodegeneration [170]. A 
disturbed CI could potentially result in decreased production of ATP [171], and  accumulation 
of ROS [172, 173]. This may lead to apoptosis [174] and a start of many mitochondrial 
disorders. CI is also shown to the most sensitive of all OXPHOS complexes. [175, 176]. One 
study shows that CIII and CIV had to be inhibited by 70-80% before major changes in oxygen 
consumption was seen, while CI showed a marked reduction in oxygen consumption already 
at 25% of inhibition [177]. Thus, even a small defect in the function or assembly of CI can 
markedly increase the levels of ROS leading to oxidative stress, mitochondrial dysfunction and 
disease. Considering this, one can understand why CI deficiencies are the most common 
disorder of the OXPHOS system (OMIM: 252010). 
With its 45 subunits, CI is the largest of all OXPHOS complexes [178-180]. These 45 subunits 
are encoded by mitochondrial or nuclear genes, and CI deficiencies can be caused by mutations 
in any of these genes or in genes encoding CI assembly factors [181-187]. CI deficiencies 
primarily affect tissues that require most energy, such as the brain and muscles. It usually starts 
from birth or affects children, and could commonly be a progressive neurodegenerative 
disorder. CI deficiencies have been associated with neurodegenerative diseases such as AD and 
PD as well as with several childhood neurodegenerative disorders. Here, the Leigh syndrome 
(LS), characterized by a rapidly progressive neurodegeneration linked to both neuronal loss 
and astrocytosis and with a normal onset during the first weeks or months after birth, is the 
most common disorder [188-193]. However, the clinical picture of CI deficiencies is highly 
diverse with varying symptoms; common symptoms include neurodegeneration, failure to 
thrive, growth retardation, poor feeding and muscle weakness [194]. Adding to that, CI 
dysfunction or mitochondrial dysfunction have in general been associated with several 
psychiatric disorders such as autism [195], bipolar disorder [196] and even AN [197]. 
1.4.4 Complex I assembly factors 
The mutations causing CI deficiencies found in mitochondrial- or nuclear-encoded CI genes 
only give a genetic explanation for about 33% of the patients [198-200]. This indicates that CI 
assembly factors may have an important role in the development of the remaining CI 
deficiencies cases [185]. The failure to assemble a properly functioning CI has been shown to 
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be a great contributor to mitochondrial diseases [153]. The process of assembling 
mitochondrial CI involves, at different steps of the process, at least fourteen known assembly 
factors [180, 201-211] and three putative assembly factors [207, 212, 213]. Pathological 
mutations causing CI deficiencies have so far been found in ten CI assembly factors (Table 1). 
Mutations in CI assembly factors cause diseases such as Leigh syndrome, leukodystrophy, 
cardiomyopathy, fatal lactic acidosis and encephalopathy, with Leigh syndrome being most 
common.   
Table 1 
Putative assembly factors are in bold. 
 
Assembly factors of human complex I 
GENE 
NAME 
OTHER 
NAME 
DISEASE CAUSING 
MUTATION FOUND PUBLICATIONS
 
NDUFAF1 CIA30 X [211, 214-216] 
NDUFAF2 B17.2L X [199, 202, 217-221] 
NDUFAF3 C3orf60 X [206, 222] 
NDUFAF4 C6orf66 X [206, 222] 
NDUFAF5 C20orf7 X [214, 223-225] 
NDUFAF6 C8orf38 X [226] 
NDUFAF7 C2orf56  [227] 
ECSIT   [203] 
ACAD9  X [228-234] 
TMEM126B  X [209, 235] 
NUBPL IND1 X [199, 236-239] 
FOXRED1  X [199, 240, 241] 
TIMMDC1 C3orf1  [207] 
TMEM70   [242] 
COA1 C7orf44  [213] 
TMEM186 C16orf51  [212] 
ATP5SL   [207] 
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1.4.4.1 Ndufaf1 
NADH dehydrogenase [ubiquinone] 1 alpha sub-complex assembly factor 1 (NDUFAF1) gene 
encodes a CI assembly factor protein for CI. Knocking down the Ndufaf1 gene in a cell system 
results in 50% decrease of CI activity and 40% reduction of fully assembled CI, while 
overexpression of Ndufaf1 gene leads to increased CI expression [201]. So far, there are three 
reports of disease-causing mutations found in the Ndufaf1 gene. One of them reported that the 
mutation in the Ndufaf1 gene results in markedly reduced CI activity in a patient that presented 
FTT at 11 months of age [214]. In the other two cases the Ndufaf1 mutation caused 
hypertrophic cardiomyopathy or leukodystrophy, the latter a disorder characterized by 
degeneration of the white matter in the brain [215, 216]. 
1.4.5 Mitochondrial involvement in neurodegenerative diseases 
Neurodegenerative disorders are characterized by a relatively selective neuronal cell death. 
Various neurodegenerative disorders affect different parts of the brain and therefore also show 
different symptoms. Neurons have a high-energy demand as well as a limited regenerative 
capacity, making them particularly sensitive to damage caused by oxidative stress [243]. That 
in combination with a mitochondrial dysfunction can lead to neuronal cell death, showing the 
importance of having ‘intact’ mitochondria for a healthy neuron. Damaged mitochondria can 
result in increased production of proapoptotic factors and ROS, changes that can lead to 
neuronal damage [159]. Indeed, several studies show impaired mitochondrial function, 
increased production of ROS and oxidative stress in many neurodegenerative diseases. In many 
studies, the impaired mitochondrial function is considered to be a cause rather than a 
consequence of the neurodegeneration [244-247].  
1.4.5.1 Complex I Dysfunction and Parkinson’s Disease 
The first sign of a mitochondrial dysfunction in relation to a neurodegenerative disease was 
detected in PD [248]. The symptoms seen in PD patients are a consequence of the 
neurodegeneration and loss of dopamine (DA) neurons in the substantia nigra. The 
degeneration of these neurons has been correlated with CI dysfunction and increased oxidative 
damage [248-251]. The substantia nigra, as well as the cortex of PD patients show decreased 
CI activity [252]. PD brains show oxidatively damaged CI subunits, leading to misassembly 
and functional impairment of CI [250].  
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1.5 INSULIN AND THE REGULATION OF GLUCOSE HOMEOSTASIS 
In the endocrine pancreas, we find β-cells producing insulin and α-cells producing glucagon. 
α-cells and β-cells are located in clusters called the islets of Langerhans. We also find other 
cells producing other hormones, such as delta cells secreting somatostatin and gamma cells 
secreting pancreatic polypeptide. β-cells sense the levels of blood sugar, and release insulin in 
response to elevated blood glucose concentration in order to reduce the high glucose 
concentration. The insulin secretion from the β-cells starts by the uptake of glucose via the type 
2 glucose transporters (GLUT2). After the entry into the cell, glucose is phosphorylated by the 
enzyme glucokinase. Glucose is then further metabolized during the glycolysis to create ATP, 
resulting in an intracellular increase in the ATP/ADP ratio. This increase results in closure of 
the ATP-sensitive potassium channels, preventing the potassium ions from crossing the cell 
membrane. This in turn results in an increased concentration of potassium ions inside the cell 
and thereby a rise in the positive charge inside the cell, causing membrane depolarization. As 
a result of this, the voltage-gated Ca2+ channels transport calcium ions into the cell. The increase 
in intracellular calcium concentrations results in release of insulin from the β-cells into the 
blood (Fig. 3) [253, 254]. 
The role of the secreted insulin is to reduce the blood glucose concentration by promoting the 
absorption of glucose from the blood [71]. Insulin does this by stimulating absorption of 
glucose from the blood to supply tissues, such as skeletal muscles, with glucose for energy 
production. Insulin also stimulates various tissues to absorb and store unused, left over glucose: 
in the liver and muscles that store as glycogen or in the fat tissue that converts glucose to 
triglycerides for storage. This is done when insulin molecules bind to their insulin receptor, that 
in turn promotes the uptake of glucose into the various tissues through the type 4 glucose 
transporter (GLUT4).  
Insulin has the important role to prevent too high blood glucose levels, that are dangerous to 
the body; however, it is also important to regulate the insulin levels in the body, since too much 
insulin can result in dangerously low glucose levels, i.e. hypoglycemia. The assignment of the 
enzyme insulinase, found in the liver and kidney, is to ensure that insulin levels are regulated, 
by breaking down insulin circulating in the blood. 
The stored glucose, in the form of glycogen and triglycerides, is used as a backup fuel source, 
when blood glucose levels decrease. The assignment for the α-cell-secreted glucagon is to give 
access to the stored glucose during times, when blood glucose levels fall. This is done by 
glucagon binding to receptors in specific tissues, resulting in activation of the enzyme glycogen 
phosphorylase which hydrolyses the stored glycogen to glucose. 
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Fig. 3 Insulin secretion in β-cells is triggered by rising blood glucose levels. Starting with the uptake of glucose by the GLUT2 
transporter, the glycolytic phosphorylation of glucose causes a rise in the ATP:ADP ratio. This rise inactivates the potassium 
channel that depolarizes the membrane, giving the inside of the cell a positive charge as shown by the red dots, causing the 
calcium channel to open allowing calcium ions to flow inward. The rise in levels of calcium leads to the exocytotic release of 
insulin from their storage granule. Image modified from Beta cell biology consortium 2004. 
1.5.1 Insulin resistance 
Insulin resistance is described as the inability of insulin to regulate the blood glucose levels in 
the body. This can lead to too much glucose circulating in the blood, a condition called 
hyperglycemia. Hyperglycemia can result in metabolic syndromes such as obesity and diabetes 
[255]. 
Diabetes mellitus is a metabolic disease and is characterized by abnormally elevated blood 
glucose levels, i.e. hyperglycemia. The hyperglycemia seen in diabetes mellitus is caused by 
either an inability of the body to produce insulin or an inability to produce insulin in sufficient 
amounts. In both cases the body cannot maintain the glucose homeostasis. There are two types 
of diabetes mellitus, the insulin dependent T1D and the insulin independent T2D. T1D is an 
autoimmune disease and is caused by destruction of the insulin-producing β-cells, resulting in 
hyperglycemia. T1D has an early onset. T2D is characterized by a slow continuous degradation 
of the glucose homeostasis as a result of insulin resistance and β-cell dysfunction, leading to 
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insufficient production and secretion of insulin. This will eventually result in a complete failure 
of the islet to secrete sufficient insulin to maintain glucose homeostasis. There are several risk 
factors associated with the development of T2D, some of which are disturbed eating habits, 
obesity and genetic predisposition [256]. 
Several factors have been shown to play a role in β-cell dysfunction and insulin resistance. 
Mitochondrial dysfunction, elevated levels of ROS and oxidative stress as well as hypothalamic 
inflammation are all implicated in pancreatic β-cell dysfunction. By providing ATP to support 
insulin secretion, mitochondrial oxidative phosphorylation is one of the important factors for a 
well-functioning insulin secretion, and an impaired mitochondrial oxidative phosphorylation 
has been associated with islet inflammation, β-cell dysfunction and the development of 
diabetes. In addition, mitochondrial dysfunction results in elevated levels of ROS and oxidative 
stress.  Due to their low antioxidant capacity, β-cells are known to be extremely sensitive 
towards oxidative stress, and it is likely that oxidative stress induced by ROS is strongly 
involved in the impairment of β-cell function during the development of diabetes. Furthermore, 
oxidative stress is related to apoptosis, and loss of β-cell function caused by enhanced apoptosis 
is also an important factor in the development of diabetes [132, 257-261]. 
1.6 THE ANORECTIC ANX/ANX MOUSE 
This thesis is based on a genetic animal model with a spontaneous mutation causing anorexia 
and starvation in mice. The anorexia (anx) mutation arose at Jackson laboratory in 1976 and is 
an autosomal recessive mutation characterized by poor appetite resulting in decreased food 
intake, reduced stomach content and body weight as well as starvation [31]. The anx/anx mouse 
develops growth failure and emaciated appearance, and dies at around 3 weeks of age, most 
likely because of the severe starvation [31]. No abnormal appearance is observed at birth, 
however, 5-8 days after birth the mice start to develop abnormal neurological behaviors, such 
as head weaving, body tremors, hyperactivity and uncoordinated gait. Experimental data have 
excluded all anatomical problems. Thus, no abnormalities in organs or in histology and 
anatomy of the gastrointestinal system have been found, and no biochemical defects are seen 
in the blood. The feeding pattern of these mice show a normal distribution, meaning that the 
daily changes in stomach content over time, are very similar between anx/anx and their normal 
wild-type (wt) littermates, indicating that the initiation of feeding is normal in the anx/anx 
mouse. However, at some point, around day 5 the anx/anx mice start to eat significantly less 
than their wt littermates, shown by the amount of food ingested, which then is not sufficient to 
sustain normal growth; this suggests a decreased appetite, indicating that the anx/anx mice 
cannot regulate the amount of food that they consume [31] (Fig. 4).  
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The anorexigenic neuropeptides POMC/CART and the orexigenic neuropeptides NPY/AgRP 
in the hypothalamus have been studied using both in situ hybridization (ISH) and 
immunohistochemistry (IHC). In Arc of wt mice, starvation is associated with an increase of 
the NPY and AgRP mRNA levels indicating activation of the orexigenic pathway, and a 
decrease of POMC and CART mRNA levels reflecting inhibition of the anorexigenic pathway. 
This represents a normal response to energy deficiency. In the anorectic anx/anx mice these 
systems do, however, show dramatic and aberrant expression patterns and levels in the 
hypothalamus [77, 262-271], even though somewhat different results have been reported in 
anx/anx mice. Some studies have shown NPY mRNA levels to be unchanged at P21 [266, 270], 
another one has shown an increase of both NPY and AgRP mRNAs [268]. IHC studies at P21 
showed that AgRP and NPY neuropeptides are accumulated in the cell bodies in the Arc and 
that the density of NPY- and AgRP-positive fibers is reduced in all hypothalamic projection 
areas studied, e.g. PVN, LHA, DMH and Arc, when comparing anx/anx and wt mice [77, 263, 
266, 268].  
Alterations can also be seen in the POMC/CART neurons in the anx/anx Arc, including 
decreased mRNA levels of POMC and CART, as well as a reduced density of NPY receptor 
Y1-positive dendrites and cell bodies of the POMC neurons [262, 263]. An inhibition of these 
neurons is also seen during starvation in wt mice, indication a normal response to starvation. 
However, the decreased levels of mRNA for the NPY receptor Y1, which is a marker for 
POMC neurons, indicate that the POMC mRNA decrease could be a result of a decreased 
number of neurons. Also, using IHC, by P21, the anx/anx mice show fewer hypothalamic 
fibers immunoreactive (ir) for α-MSH, one of the POMC peptides, and CART [262, 263]. 
These results indicate a neurodegeneration in the anorexigenic POMC system of anx/anx mice 
[77]. 
When studying the serum leptin levels, it is shown that, from around postnatal day 8, the 
anx/anx mice show significantly reduced serum leptin levels, which is consistent with the low 
amounts of adipose tissue in anx/anx mice [262]. Reduced levels of leptin should increase the 
hunger signals, resulting in increased food intake. The fact that an opposite response to low 
leptin levels is seen, represents a further sign of a hypothalamic problem in feeding behavior. 
In addition, the anx/anx mice show an increased density of serotonergic fibers in the Arc as 
well as in the olfactory bulb, frontal cortex, hippocampus and cerebellum [264, 270]. Serotonin 
has been shown to inhibit food intake, appetite, and to inhibit the activity of NPY neurons 
[272]. Other studies have also shown alterations in the dopaminergic [269] and the 
noradrenergic [271] systems in anx/anx mice.  
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Moreover, both inflammation and apoptosis have been related to the anx/anx mice, as shown 
in two microarray studies. The gene expression study by Lachuer et al. [273] showed 
hypothalamic inflammation in the anx/anx mouse and suggested that this hypothalamic 
inflammatory process could be the cause of the anorectic phenotype in the anx/anx mouse. The 
other study, by Mercader et al. [274], showed increased levels of deregulated genes involved 
in cell death and morphology. They also detected alterations in several signaling pathways for 
importance of energy homeostasis. 
An earlier study on the anx/anx mouse showed increased levels in cell proliferation and 
apoptosis in dentate gyrus of the anx/anx mice [275]. The apoptotic protease activating factor 
1 (APAF1) is another gene shown to be related to the phenotype of the anx/anx mice [276].  
A higher expression of the neurotrophin receptor tyrosine kinase 3 (NTRK3) gene has been 
detected in the hypothalamus of the anx/anx mouse. Also, this gene shows a strong and 
significant association to eating disorders [277].  
A recent study on the anx/anx mouse identified a mutation in the tyrosine receptor kinase 3 
(Tyro3) gene and showed that Tyro3-transgenic anx/anx mouse doubled the weight and 
survival as well as expressed almost normal numbers of hypothalamic NPY neurons. However, 
since the specific mutation in the Tyro3 gene is also present in several other mouse strains, and 
none of these strains display any of the anx phenotypes, the Tyro3 variant are excluded as the 
anx-mutation [278].  
 
 
Fig. 4 Image showing an anorectic anx/anx mouse (to the left) and its normal wt littermate (to the right) at P21.  
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2 AIMS OF THE STUDY 
The overall goal of this thesis is to increase the knowledge about the molecular mechanisms 
involved in energy homeostasis, i.e. the regulation of food intake and energy expenditure, in 
particular the role of (neuro)inflammation and mitochondrial dysfunction. 
Specific aims are: 
1. To assess the role of hypothalamic neuroinflammation on the regulation of food intake in 
an anorectic condition (Paper I-II). 
2. To assess the role of mitochondrial dysfunction on the regulation of food intake in an 
anorectic condition (Paper III and V). 
3. To assess the role of pancreatic inflammation on glucose homeostasis and ß-cell function 
in an anorectic condition (Paper IV) 
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3 MATERIALS & METHODS 
3.1 ANIMALS (PAPER I-V) 
All animal experiments performed in this thesis were approved by the local ethical committee, 
Stockholm Norra Djurförsöksetiska Nämnd. Originally the heterozygous anx breeding pairs 
(B6C3Fe-a/a-anx A/+ a) were obtained from The Jackson Laboratory [31]. The breeding pairs 
were used to set up an intercross. All pups (anx/anx, +/+, anx/+) were housed in ventilated 
cages at room temperature (22°C) with a 12-h light-dark cycle and had full access to food and 
water, as well as unlimited access to their mother. Genotyping was performed using simple 
sequence-length polymorphism (SSLP) markers mapped to the sub-chromosomal region, 
where the anx mutation is located [31]. 
3.2 MAPPING OF THE ANX-GENE (PAPER III) 
The anx-interval had previously been mapped to a 20cM interval on mouse chromosome 2 
[31]. To further narrow down the anx-interval two intercrosses were set up. Cross 1 was set up 
between (B6C3Fe-anx A/+ a × B6C3H F1) and resulted in 2050 F2 progeny (4100 meioses). 
Cross 2 was set up between (B6C3Fe-anx A/+ a and CAST/Ei) and resulted in 372 F2 progeny 
(744 meioses), and the results from this cross were analyzed. DNA was prepared from the tail 
tips. SSLP markers mapped to this subchromosomal region were used to genotype all mice. 
The previously reported chromosomal map position linked to chromosome 2 was the basis for 
choosing the D2Mit markers. The additional markers, i.e. the Jojo primer pairs, were designed 
around simple sequence repeats: Jojo5 spans a GT-repeat and Jojo8 a CA-repeat, located in the 
anx-interval.     
3.3 IN SITU HYBRIDISATION (PAPER II) 
ISH is a method used to study cellular expression and localization of mRNA in specific tissues 
and cells. The ISH used in this thesis was based on radioactively labelled oligoprobes 
complementary to 48 nucleotide bases, and was used to study the expression of MHC class I 
related genes in anx/anx and +/+ mice.  
Brain tissue from anx/anx and +/+ mice were frozen on dry ice and cut in thin sections using a 
cryostat. Immediately after cutting, the brain sections were mounted on glass slides. The anti-
sense oligoprobes for MHC Class I were synthesized by Cybergene AB (Huddinge, Sweden). 
The isotopic-labeling of the oligoprobes at the 3 end was done enzymatically. The labeled 
probes were hybridized to the brain sections by emerging the slides in a cocktail including the 
oligoprobes after which the slides were washed, air-dried, dipped in NTB2 nuclear emulsion 
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(Kodak, Rochester, NY), exposed, developed and then analyzed a microscope equipped with a 
dark-field condenser and a digital camera.  
The validity of the results obtained with ISH is dependent on the specificity of the probe. To 
test the probe specificity, we incubated the slides in a mixture including both labeled probe and 
an excess of unlabeled probe, a procedure that always resulted in loss of signal. 
3.4 HISTOCHEMISTRY (PAPER I, II, III) 
IHC is a method used to detect expression of specific proteins/peptides and their cellular 
localization in different tissues. Also, using double or triple-labeling with several markers a co-
localization of different proteins can be studied.  
In Paper I, II and III we used IHC to detect expression of AgRP, TLR2, ionized calcium 
binding adapter 1 (Iba1), a marker for activated microglia cells, MHC Class I subunit β2 
microglobulin (β2m), active caspase 6 (actCasp6), an enzyme involved in axonal degeneration, 
the Y1R and SOD2 in anx/anx and +/+ hypothalamus. In Paper IV we used IHC to study 
pancreatic and cultured islets to detect expression of Iba1, F4/80, a marker for macrophages, 
the pancreatic hormones; insulin, glucagon and somatostatin, and Ki-67, a marker for 
proliferation. 
For IHC analysis, mice were anesthetized with isoflurane and perfused via the ascending aorta 
with Tyrode’s Ca2+-free solution, followed by a mixture of paraformaldehyde and picric acid. 
Brains and/or pancreas were then rapidly dissected and immersed in the same fixative for 90 
min followed by overnight incubation in sucrose solution. Sections were cut on a cryostat, 
thaw-mounted on to slides and then further processed for either indirect IHC technique or the 
tyramide signal amplification (TSA)-plus system. From this point the sections were used for 
TUNEL labeling as described in section 3.4.1. 
In the indirect method, we first incubated overnight with a primary antiserum, directed against 
our target of interest, followed the next day by incubation with secondary antibodies, directed 
against the species that primary antisera were raised in and conjugated with a fluorescent 
marker. 
When using the TSA-plus system, we first incubated with primary antisera overnight, followed 
by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies and then 
with biotinyl tyramide. The function of the HRP-conjugated antibody is that HRP enzyme 
catalyzes the deposition of several activated tyramide molecules. The advantage is that the 
additional step in the TSA-plus system amplifies the signal.  
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After IHC with either technique, the samples were analyzed using a fluorescence microscope 
and/or a confocal scanning microscope.   
3.4.1 TUNEL Labeling (Paper II) 
Terminal dUTP Nick End Labeling (TUNEL), a marker for cell death, was used to investigate 
the number of apoptotic cells in the anx/anx hypothalamus. TUNEL labeling is a method used 
to detect DNA fragmentations, which results from apoptotic signaling cascades. This is done 
by enzymatical labeling of the terminal end of the nucleic acids in apoptotic cells by terminal 
transferase [279]. 
For TUNEL labeling, the procedure is the same as for IHC up till the sections are thaw-mounted 
on to slides. The sections were then pretreated with H2O2 in methanol to block endogenous 
peroxidases. Following this step, a permeabilization solution was applied to the sections before 
the TUNEL reaction mixture was added. Sections were then washed, mounted and finally 
analyzed in a fluorescence microscope.  
3.4.2 Dihydroethidium injections (Paper III) 
To evaluate whether increased production of ROS occurs in the hypothalamus of anx/anx mice 
we performed dihydroethidium (DHE) injections. DHE is oxidized to fluorescent ethidium 
when reacting with superoxide [280]. To measure hypothalamic ROS production an 
intravenous DHE injection was given once via the femoral vein to anx/anx and wt mice at P21. 
Two hours after injections the mice were deeply anaesthetized and sacrificed by perfusion with 
fixative (as in 3.4). Sections were cut on a cryostat and processed according to indirect IHC 
methods to visualize the AgRP and NPY arcuate neurons and microglia. Red fluorescent dot-
like structures in the Arc were counted in anx/anx and +/+ mice.  
3.4.3 Pancreatic and cultured islets (Paper IV) 
We performed IHC to study inflammation in intact pancreas and in isolated islets cultured 
overnight using Iba1 and F4/80, which both are markers for macrophages/microglia. 
Immunohistochemically double-labeling was done with antiserum to Iba1 and insulin, or Iba1 
and F4/80. We also analyzed the pancreatic hormones glucagon and somatostatin, and Ki-67, 
the latter a marker for proliferation.  
In order to study intact pancreas, mice were anesthetized with isoflurane, perfused with 
formalin fixative and then further processed for IHC as described above. Sections were 
incubated with antiserum against Iba1, F4/80, glucagon, somatostatin or Ki-67 overnight at 
4°C, followed by incubation with horseradish peroxidase-conjugated secondary antibody, and 
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processed with the TSA-plus fluorescein system. For double-labeling, the TSA was followed 
by incubation with antibodies against insulin or Iba1, and another incubation using secondary 
antibodies conjugated with Cy3 or rhodamine red. Finally, the sections were counterstained 
with 4,6-diamidino-2phenylindole (DAPI), a blue fluorescent stain binding to AT regions of 
DNA. 
For IHC on isolated islets cultures, the isolation of the islets was performed as described in 
section 3.12. After culturing the islets overnight, they were fixed for 20 min in ice-cold 
paraformaldehyde and picric acid fixative, rinsed in phosphate-buffered saline and frozen on 
dry ice. The islets were then cut on cryostat and thaw-mounted on to slides. IHC was performed 
as described above (3.4). 
3.5 MICROARRAY (PAPER III)  
Microarray expression analysis is a method used to evaluate differences in gene expression in 
a large set of genes. We used Affymetrix Mouse Genome 430 2.0 Array (Affymetrix Inc.) to 
detect differences in expression of genes in the Arc between anx/anx and +/+ mice at P21. 
RNeasy kit (Qiagen) was used to prepare total RNA from the Arc using 3 anx/anx and 3 +/+ 
mice. cRNA was synthesized from total RNA and then hybridized to the Array. MAS 5.0 
software, was used to analyze the data files. The expression values were determined by the 
MAS 5.0 software, and the genes were included for comparison analysis, if expression was 
present in at least four out of six arrays. After that we compared all anx/anx and all +/+ samples, 
giving a total of nine comparisons, and the genes were included for pathway analysis, if the 
expression was altered in at least seven out of the nine comparisons.   
3.5.1 Ingenuity Pathway Analysis (Paper III) 
The microarray expression analysis identified a large set of genes with altered expression in 
the Arc comparing anx/anx and +/+ mice. To identify the top canonical pathways involved in 
the phenotype of the anx/anx mice, these genes were used to perform Ingenuity Pathway 
Analysis (IPA) (Ingenuity Systems, www.ingenuity.com). Genes with a fold change ≥1.4 
increase or decrease were included, giving 132 up- and 73 down-regulated genes in the IPA 
analysis. All pathways included had a P-value < 0.05. 
3.6 REAL-TIME PCR (PAPER III) 
Real-time PCR was used to analyze the expression levels of the candidate gene for the 
candidate anx-mutation, Ndufaf1, in several tissues. The tissues analyzed were brain, heart, 
kidney, lung, pancreas, liver and skeletal muscle. Total RNA for both anx/anx and wt mice at 
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P21 was prepared from these seven different tissues, where after cDNA was synthesized from 
total RNA by reverse-transcription. The samples were then analyzed for the expression of 
Ndufaf1 using Taqman real-time PCR (7900 HT Fast Real-time PCR system, Applied 
Biosystems Inc., Foster City, CA). The amplification of the genes was performed in duplicates. 
The calculation of relative gene expression was done using the standard curve method. 
Quantity was calculated using mean values of the duplicates relative to those for well-known 
house-keeping genes, with a specific house-keeping gene chosen for each specific tissue.  
3.6.1 Mitochondria count (Paper III) 
A mitochondrial count was performed with SYBR green real-time PCR to make sure that the 
defects in the OXPHOS system seen in the anx/anx mice were not due to a reduced number of 
mitochondria. DNA from four anx/anx and four +/+ hypothalamus were prepared using 
DNeasy Qiagen (Qiagen, Washington DC, Maryland). Probes directed against markers for 
mitochondrial DNA (cytochrome B and cox1) and nuclear DNA (cyclophyllin) were used to 
calculate the proportions of mitochondrial DNA/genomic DNA in hypothalamus from anx/anx 
and +/+ mice. To quantify the number of mitochondria the Sequence detector system ABI-
prism 7000 (Applied Biosystems Inc.) was used. 
3.7 SDS PAGE (PAPER III, V)  
Sodium dodecyl sulfate – polyacrylamide gels (SDS-PAGE) is a method used to separate 
proteins according to their molecular weight. We used SDS-PAGE to analyze protein levels of 
NDUFAF1, AMPK and glucose transporters (GLUTs) in total brain and hypothalamic tissue.   
The tissue was homogenized, centrifuged and boiled, where after the protein concentration was 
determined using BCA Protein Assay kit (Pierce, Thermo Scientific). The proteins were 
separated on a gel and were then transferred to a membrane, and detected by immunoblotting 
using primary antibody against the protein of interest. Secondary antibodies conjugated with 
horseradish peroxidase were then applied, the signal developed, exposed to film and the 
intensities of the bands were determined with Image J or MultiGauge (Fujifilm, Tokyo, Japan). 
Data were normalized to the expression of β-actin.  
3.8 BLUE NATIVE PAGE (PAPER III) 
Blue Native PAGE (BN PAGE) was used to determine the amount of fully assembled 
mitochondrial protein CI and sub-complexes in the OXPHOS system. BN PAGE is a non-
denaturating blot, which means that it does not separate the protein complexes, but keeps them 
together as they are in the cell cytoplasm. Hypothalamus was dissected form anx/anx and wt 
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mice at P21, whereafter crude hypothalamic mitochondria were isolated as previously 
described [281]. BCA Protein Assay kit (Pierce, Thermo Scientific) was used to determine 
mitochondrial protein concentration and NativePAGETM Sample Prep Kit (Invitrogen) for 
mitochondrial protein preparation, where after BN-PAGE was performed. The mitochondrial 
proteins were run on NativePAGETM gradient gels (Invitrogen). During the electrophoresis 
with BN-PAGE coomassie blue dye is used, giving the complexes a negative charge allowing 
separation. After electrophoresis, gels were further processed for SDS PAGE to detect CI, CII 
and TOM40, used for normalization, or for in-gel activity staining of CI (see 3.8.1).   
3.8.1 In- Gel Activity Assay (Paper III, IV) 
In-gel activity staining was used for the measurement of CI activity in the hypothalamus and 
in crude mitochondria from anx/anx and wt islets. Immediately after BN-PAGE gel 
electrophoresis, the gels were used for CI in-gel activity staining. The gel was immersed in a 
solution containing Tris-HCl, NADH and Nitro Blue tetrazolium (NBT). The intensities of the 
bands were analyzed using Image Gauge software. Data were normalized to the expression of 
TOM40, which is a marker for mitochondrial outer membrane.  
3.9 SEQUENCING (PAPER III) 
Sequencing of the candidate gene Ndufaf1 was done to identify sequence alterations between 
anx/anx and +/+ mice. Genomic DNA and cDNA were prepared, followed by PCR 
amplification and sequencing using ABI 3730 DNA Analyzer and BigDye Terminator v3.1 
Cycle Sequencing kit (Applied Biosystems Inc, Foster City, CA). In brief, genomic DNA was 
prepared using mouse tail tips and standard salting-out procedures. RNA/cDNA was prepared 
using total brain, and RNA was extracted using TRIZOL Reagent. After DNase treatment of 
the RNA (TURBO DNA-free; Ambion), cDNA was synthesized by reverse-transcription of 
total RNA with oligoDT (SuperScript III First Strand Synthesis System for RT-PCR; 
Invitrogen).  
3.10 ALLELE SPECIFICITY (PAPER III) 
Allele specificity analysis was performed to evaluate whether the downregulation in Ndufaf1 
is related to the mutation rather than a secondary effect of the starvation. Upon sequencing the 
Ndufaf1 gene a silent T/C SNP was found (Ensembl gene ID ENSMUSG00000027305 
Ndufaf1 +87 T/C). This SNP was used to separate the expression level of the anx-allele from 
the wt-allele. Total brain from four heterozygous (anx/+) mice was used, since these mice carry 
one copy of each allele and show no disease phenotype. RNA and DNA were isolated using 
TRIZOL, and cDNA was prepared in triplicates from the RNA. Duplicates of the DNA and 
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cDNA were PCR-amplified over the T/C SNP, where after the levels of the allele expression 
were quantified using PyroSequencing (PSQ 96; Qiagen). Imbalanced expression levels of the 
two alleles were obtained by comparing the ratio of the mean peak heights from the two alleles 
in cDNA to the corresponding peak heights in genomic DNA [peak height anx allele 
(cDNA)/peak height wt allele (cDNA)]/[peak height anx allele (gDNA)/peak height wt allele 
(gDNA)].  
3.11 RESPIROMETRY (PAPER III) 
The efficiency of the different complexes in the OXPHOS system was studied in the anx/anx 
hypothalamus by high-resolution respirometry utilizing an Oxygraph-2K (Oroboros, 
Innsbruck, Austria). Using this device one can evaluate the rate of respiration by measuring 
oxygen consumption. Hypothalamus was dissected and homogenized in a buffer named MIR05 
including EGTA, MgCl2, KH2PO4, HEPES, sucrose, taurine, BSA and K-lactobionate. The 
hypothalamic tissue suspension was added to the Oxygraph-2K chamber. After saturating the 
respiration medium with oxygen, substrates such as glutamate and ADP were added to measure 
different states of respiration. 
First, basal oxygen flux (leak) from CI was assessed by adding the CI substrates malate and 
pyruvate. In order to couple electron transfer to ATP production, i.e. to measure the coupled 
respiration from CI, ADP and glutamate were added. The CII substrate succinate was added to 
assess oxygen flux from CI and CII. Maximal capacity of the electron transfer system by CI 
and CII was assessed by adding the uncoupler carbonyl cyanide-4-(trifluoromethoxy) 
phenylhydrazone (FCCP). Electron transport through CI was then inhibited by adding 
rotenone, and through CIII by antimycin A. After inhibiting CI and CIII we assessed the 
remaining oxygen flux, i.e. the oxygen flux independent of the electron transfer system, which 
was subtracted from each of the previous steps.  
3.12 PANCREATIC ISLET ISOLATION (PAPER IV) 
Isolated pancreatic islets were processed for several analyzes, e.g. of glucose homeostasis, 
static and dynamic insulin secretion, and for IHC to study markers of inflammation. For 
isolation of pancreatic islets from anx/anx and wt mice, the collagenase method was used that 
allows preservation of islets [282]. Pancreas was inflated with Hank’s balanced salt solution 
containing collagenase. After digestion, islets were picked manually under a microscope and 
cultured overnight in RPMI-1640 medium containing glucose.  
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3.13 PANCREATIC ISLET SIZE DISTRIBUTION (PAPER IV) 
The size of the pancreatic isolated islets from anx/anx and wt mice was determined and 
measured on micrographs using 40-100 islets/animal. 
3.14 ELISA (PAPER IV) 
Enzyme-linked immunosorbent assay (ELISA) is a method to identify the presence of different 
substances by using antibodies and color changes. An antibody linked to an enzyme binds to 
the specific antigen of interest. In the final step a substance containing the enzyme substrate is 
added, resulting in a reaction that produces a detectable signal, e.g. a change in color in the 
substrate. We used ELISA to measure insulin concentration.    
3.14.1 Intraperitoneal Glucose Tolerance Test (Paper IV) 
To analyze glucose homeostasis in anx/anx and wt mice, we used the intraperitoneal glucose 
tolerance test (ipGTT) in both fed state and after 5 h of fasting. Glucose and insulin values were 
measured in blood samples taken from the tail tip. The time points measured were 0, 30, 60 
and 90 min after the mice received a glucose injection. 0 min represents the basal state and was 
taken immediately before the mice received the glucose injection. An ip injection containing 2 
mg glucose/g body weight was given. Glucose levels were measured throughout the test using 
an Accu-Chek blood glucose analyzer (Roche Diagnostics, Indianapolis, IN). For insulin 
measurements, serum was prepared from the blood samples, and insulin levels were measured 
using Ultrasensitive Mouse Insulin ELISA kit (Mercodia, Uppsala, Sweden).     
3.14.2 Total pancreatic insulin and glucagon content (Paper IV) 
We analyzed the pancreatic hormones, insulin and glucagon in pancreas. For the measurement 
of total insulin and total glucagon content, pancreatic hormones were extracted from whole 
pancreas with acid ethanol, where after the extracts were analyzed using Ultrasensitive Mouse 
Insulin ELISA or Glucagon ELISA (Mercodia). Total protein content was measured in the 
extracts with BCA Protein Assay kit (Thermo Scientific) and was used for normalization.  
3.14.3 Static insulin release (Paper IV) 
Static insulin release was measured in isolated anx/anx and wt islets by stimulation with 3 mM 
glucose, 11 mM glucose and 25 mM KCl. The stimulation with both glucose and KCl enabled 
the measurement of insulin release at different stages of the insulin-release-pathway. Islets 
were isolated as described above, and groups of 3 islets/genotype were first preincubated in 
Krebs-Ringer bicarbonate buffer (KRBB) containing 3 mM glucose. The islets were then 
incubated in the same buffer containing low glucose or high glucose concentration or KCl. The 
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media were analyzed for insulin levels using Ultrasensitive Mouse Insulin ELISA kit 
(Mercodia), and the values were normalized by the number of islets. 
3.14.4 Free fatty acids in serum (Paper IV) 
We evaluated the levels of free fatty acids (FFAs) in serum from nonfasted anx/anx and wt 
mice. This was done by the use of Free Fatty Acid Quantification kit (Sigma-Aldrich). The 
concentration of FFAs is determined by a coupled enzyme assay, resulting in a fluorometric 
product which is proportional to the FFAs concentration in the serum analyzed.  
3.15 ARCDIA TPX ASSAY (PAPER IV) 
The ArcDia TPX technology (Arc-Dia Group, Turku, Finland) was used for the measurement 
of insulin concentrations in pancreatic islets from anx/anx and wt mice. This system detects the 
signal of a fluorescent labeled antibody by two-photon excitation from the surface of each 
individual microsphere. The technique uses the antibody-antigen interaction, and an 
immunecomplex consisting of monoclonal antibody, antigen and fluorescent labelled 
monoclonal antibody is formed in proportion to the analyte concentration. Both the bound 
tracer, i.e. the specific signal, and the unbound tracer, i.e. the background signals, are recorded. 
The levels of insulin were obtained with the help of human insulin standard curve using 
samples of known concentration.      
3.15.1 Dynamic insulin release (Paper IV) 
In addition to the static insulin measurement with ArcDia in isolated pancreatic islets, dynamic 
insulin release was also monitored. This allows for insulin measurement over time analyzed 
during continually perfused islets at 3mM basal glucose concentration or stimulated with 11 
mM glucose or 25 mM KCl. For measurement of dynamic insulin release, islets were isolated 
as described above, and 30 islets/genotype were preincubated in KRBB containing 3 mM 
glucose. The islets were immobilized and continuously perfused, and stimulated with 3 mM 
glucose followed by 11 mM glucose, 3 mM glucose and lastly 25 mM KCl. Samples were 
collected every second minute, and insulin was measured in using the ArcDia TPX assay (Arc-
Dia Group). 
3.15.2 Islet insulin content (Paper IV) 
We measured the insulin content in isolated islets. For this, isolated islets from the two different 
genotypes were used. The islets were incubated with M-PER for and then centrifuged. The 
supernatant was used to analyze insulin levels with ArcDia TPX assay (Arc-Dia Group). For 
total protein content, islets were homogenized in RIPA buffer, and total protein content was 
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measured in the extracts using BCA Protein Assay kit (Thermo Scientific). Total insulin 
content in anx/anx and wt pancreas was normalized against total pancreatic protein content. 
3.16 SPECTROPHOTOMETRIC ANALYSIS 
Spectrophotometric analysis was used to measure cytoplasmic free Ca2+ concentration and 
mitochondrial membrane potential in isolated islets, as well as respiratory chain enzyme 
activities in the hypothalamus from anx/anx and wt mice.  
The spectrophotometric technique uses the attributes of light to measure concentration of 
different compounds in a solution. Different compounds having different atomic and molecular 
interactions have different absorption spectra. The spectrophotometer can measure the amount 
of light absorbed by the solution by measuring the intensity of a light beam after passing 
through a solution. 
3.16.1 Measurement of [Ca2+]i (Paper IV) 
We measured changes in free cytosolic Ca2+ concentration [Ca2+]i ,when islets from anx/anx 
and wt mice were stimulated with high glucose concentration. For the correct measurement of 
intracellular calcium concentration, we used fura 2 acetoxymethyl (AM), a fluorescent 
indicator dye for measuring intracellular calcium.  Changes in [Ca2+]i were measured as the 
340/380 nm fura-2 fluorescence ratio. Islets isolated from anx/anx and wt mice were incubated 
for 50 min at 37°C in KRBB containing 3 mM glucose and fura 2 AM. A single islet was 
transferred to a chamber and fixed to the cover slip with PuraMatrix Peptide Hydrogel. The 
chamber was mounted on a microscope connected to a Apex Fluorolog spectrophotometer. 
Changes in [Ca2+]i were measured over a period of time as the islets were continuously 
stimulated with 11 mM glucose, followed by 3 mM glucose and finally 25 mM KCl. 
3.16.2 Mitochondrial membrane potential of pancreatic islets (Paper IV) 
Mitochondrial membrane potential (MMP) was measured in isolated islets from anx/anx and 
wt mice. This was done using Rhod123, a fluorescent dye. This dye has a negative charge and 
will therefore strive for an equilibrium across the membrane. The negative charged dye will 
accumulate in the mitochondrial membrane matrix space in inverse proportion to the MMP, so 
that a more negative (i.e. more polarized) MMP will accumulate more dye. The total force that 
drives the protons back into the mitochondria (i.e. Δp) to generate ATP is a combination of the 
MMP, which is the charge gradient, and the mitochondrial H+ concentration gradient. The 
specific measurement, using this method, is the charge gradient across the inner mitochondrial 
membrane and is not specifically a measurement of the mitochondrial proton gradient Δp.  
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Isolated islets from anx/anx and wt mice were incubated in KRBB with 3 mM glucose and 
Rhod123 for 10 min. The increased MMP, in response to the change from 3 to 11 mM glucose, 
was recorded using the same system as for the [Ca2+]i measurements. 
3.16.3 Respiratory chain enzyme activities in hypothalamus (Paper V) 
We also used spectrophotometric analysis to evaluate the enzymatic activity of the different 
complexes in the respiratory chain in isolated mitochondria from hypothalamus of anx/anx and 
+/+ mice.  
In addition, we spectrophotometrically evaluated citrate synthase (CS) activity in hypothalamic 
tissue. CS is a mitochondrial marker [283], and was used for quantitative analysis of the number 
of mitochondria in anx/anx vs wt hypothalamus. Hypothalamus was dissected and 
homogenized in a solution with Triton X-100, KH2PO4 and EDTA. The homogenate was 
centrifuged and CS activity determined in the supernatant. The assay was performed on a 
photometer. 
3.17 EX VIVO AUTORADIOGRAPHY OF HYPOTHALAMIC GLUCOSE UPTAKE 
(PAPER V) 
To analyze the degree of hypothalamic metabolism, the rate of glucose uptake in anx/anx 
hypothalamus was studied by using intra peritoneal (ip) injection of 2-deoxyglucose labeled 
with tritium, also called hydrogen-3 [3H], a radioactive isotope of hydrogen. [3H]-2-
deoxyglucose is a good marker for tissue glucose uptake, and the regional distribution can be 
assessed by tissue-sectioning followed by autoradiography.   
Prior to the ip injection of [3H]-2-deoxyglucose the mice were fasted for 5-6 hours. Brain and 
liver were dissected forty-five min after injection, which is a sufficient time for adequate 
glucose uptake [284]. Tissues were sectioned and exposed to phosphor imaging plates, which 
were analyzed using Multi Gauge 3.2 phosphorimager software (Fujifilm). The glucose uptake 
into the hypothalamus, motor cortex, thalamus and liver was calculated by the following 
formula: (μmol glucose per mL serum/dpm per mL serum) × dpm/g tissue = μmol glucose/45 
min/g tissue). 
Also, by the time of killing, blood glucose concentration was measured using an Accu-Chek 
blood glucose analyzer (Roche Diagnostics). To estimate glucose-specific activity in serum, 
the serum glucose values were calculated by multiplying the blood values by 1.15. The 
radioactivity in serum was measured with a scintillation counter.  
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3.18 ANALYSIS OF METABOLITES & ATP TURNOVER (PAPER V) 
Metabolites in the anx/anx hypothalamus were measured in the basal state and after one minute 
of ischemia. Phosphocreatine (PCr), creatine (Cr), ATP, Lactate, glucose 6-P (G6P) were 
measured with enzymatic techniques (changes in NAD(P)H) adapted for fluorometry. ATP, 
ADP, AMP and inosine monophosphate (IMP) were measured using by high-performance 
liquid chromatography (HPLC).  
For the study of the basal condition, the whole head was decapitated, immediately frozen in 
liquid nitrogen (N2) and freeze-dried, and the hypothalamus dissected out. For the 
ischemic/stress experiment, the hypothalamus was rapidly dissected out after decapitation, and 
frozen in liquid N2 and freeze-dried. The process from decapitation to freezing in N2 took 
approximately 1 min. Ice-cold perchloric acid was added to the freeze-dried tissue, that was 
kept in an ice bath for 20 min and then centrifuged. The supernatant was neutralized with 2.2M 
KHCO3 and centrifuged again. The latter supernatant was used to analyze metabolites with 
enzymatic techniques or with HPLC. Metabolite values were divided with the value for total 
Cr (PCr + Cr) and then multiplied by the mean total Cr content for the whole material. This 
was done to adjust for non-hypothalamic tissue (e.g. blood).  
Anaerobic ATP turnover was calculated by using the following equation: −2ΔATP − ΔPCr + 
(1.5Δ lactate). Δ refers to the mean difference between ischemic and basal values. 
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4 RESULTS & DISCUSSION 
4.1 IMPAIRED DEVELOPMENT OF THE NPY/AGRP SYSTEM IN THE 
ANX/ANX MOUSE (PAPER I & II) 
In Paper I, we studied the development of the NPY/AgRP system in anx/anx and +/+ mice by 
examining the AgRP distribution at different postnatal days. AgRP was used as a marker for 
the orexigenic system, since it is expressed only in  the arcuate NPY neurons [63, 65, 77], 
whereas NPY is also expressed in many other brain systems [59]. AgRP distribution was 
studied at postnatal days P1, P5, P10, P12, P15 and P21 using IHC.  
The development of the AgRP system is similar in the anx/anx and +/+ mice until P12. 
However, from this day the normal gradual increase in AgRP fiber density ceases, with a much 
weaker expression at P21 (the longest time studied). When comparing P21 and P15 the AgRP 
fiber density in anx/anx mice was significantly reduced and even disappeared in certain regions. 
At P21 we could also detect many strongly AgRP-positive cell bodies in the Arc in the anx/anx 
mice compared to +/+ mice, where only few and weakly fluorescent AgRP-positive cell bodies 
were observed.  
In Paper II we also studied the postnatal development of the POMC/CART system in the 
anx/anx and +/+ mice using IHC. This was done using antibodies directed against the NPY 
receptor Y1, since this receptor is expressed by POMC neurons and decorates their soma and 
the dendrites. We could see that the POMC/CART system develops similar to the AgRP 
neurons until P21, although no changes were seen at P15. At P21, however, there was a 
decrease in density of the dendritic processes and cell bodies of POMC neurons in the Arc 
anx/anx mice. This shows that the abnormal pattern of the POMC/CART system in anx/anx 
mice can only be detected later in the postnatal development compared to the changes in the 
NPY/AgRP system.  
Taken together, these results are indicative of degenerative processes in the hypothalamic Arc 
in the anx/anx mice, whereby the NPY/AgRP system is first affected and the POMC/CART 
system at a later stage.  
4.2 SIGNS OF INFLAMMATION IN THE HYPOTHALAMUS OF THE ANX/ANX 
MOUSE (PAPER I & PAPER II) 
4.2.1 Activated microglia and TLR2 
A second aim of Paper I was to study the underlying mechanisms for the impaired 
development of the AgRP system in anx/anx mice. One of our hypotheses was that the 
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alterations in the development of this system could be associated with an inflammatory process. 
We therefore studied the expression of Iba1, which is a marker for activated microglia [285] as 
well as TLR2. Microglia and TLR2 are both a part of the innate immune system. Microglia 
cells are activated in the presence of damaged cells and different injuries in the nervous system, 
such as virus infection or degeneration [286, 287]. TLR2 is a protein receptor that defends 
against invading pathogens and toxic cell debris, e.g. apoptotic cells [288]. Iba1 and TLR2 
were studied using IHC at the same time points as was used to explore AgRP and Y1 described 
above, e.g. postnatal days P1, P5, P10, P12, P15, P21 in anx/anx and +/+ mice.  
Our results show that the gradual decrease in AgRP fiber density starting from P12 overlaps 
with an increase in Iba1 and TLR2 immunoreactivities (irs). Starting from P12 the detection of 
activated microglia (i.e. increased Iba1 labeling) was seen in several hypothalamic and extra-
hypothalamic areas with a gradually stronger labeling at P15 and P21. This gradual increase in 
microglia activation was seen in the same areas as the decrease in density of AgRP 
immunoreactive fibers. The impaired development of the AgRP system and the overlapping 
activation of microglia of the anx/anx mouse indicate an inflammatory and/or degenerative 
process.  
In Paper I, we could also see presence of activated microglia cells close to the NPY neurons 
in the Arc. This was further studied in Paper II, using IHC and antibodies against NPY, Iba1 
and OX42, an additional marker for activated microglia. By double-labeling for either NPY 
and Iba1 or NPY and OX42 we saw that several activated microglia were tightly surrounding 
NPY/AgRP neurons. This pattern was similar to that described by Ribak et al. as a microglia-
associated type of cell death which differs from both apoptosis and necrosis [289].  
4.3 SIGNS OF NEURODEGENERATION OF THE ARCUATE NEURONS IN THE 
ANX/ANX MOUSE (PAPER II) 
In Paper II, several approaches were taken to further investigate a possible 
neurodegeneration and inflammation in the anx/anx hypothalamus. As a result, we found 
additional evidence for neurodegeneration and show indications that both the anorexigenic 
and the orexigenic neuronal populations in the hypothalamus are likely to undergo 
degeneration in the anx/anx mouse.  
First, we used IHC and ISH to study the expression and the localization of MHC class 1-related 
molecules. Expression of the MHC class I gene was found in Arc, both in neurons and in glia 
cells. We detected strong and region specific expression of MHC class I- related molecules in 
all areas that previously showed expression of activated microglia. That is in line with the 
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function of activated microglia, since they are well known to express MHC class I [124]. Glial 
cells express MHC class I during pathological conditions, such as multiple sclerosis, viral 
encephalitis and brain injury [123, 124]. However, we did not only see that the activated 
microglia cells expressed MHC class I, but also detected expression of the MHC class I co-
subunit β2m by the NPY/AgRP and POMC/CART neurons in the Arc. 
Neurons express MHC class I protein during acute inflammation and changes in electrical 
activity [119-122]. Both increased and decreased neuronal activity can result in increased MHC 
class I expression in the neurons [290, 291]. The expression of MHC class I is also important 
for the maintenance of synapses as well as for the regeneration after injury [292], indicating 
that MHC class I could be expressed to save the abnormally active neuron from synaptic 
elimination. 
We therefore continued studying the activity of the hypothalamic neurons in anx/anx and +/+ 
mice by using two markers for cellular reactivity, cFOS and ΔFosB  [293]. We could see that 
most of the β2m-expressing neurons in the Arc of the anx/anx mice had no or very low 
expression of Fos B. This indicates that the neurons expressing the MHC class I subunit are 
‘silenced’ or have a very low activity.  
In Paper II, we further analyzed the degenerative process in the hypothalamus of the anx/anx 
mice by using markers for cell death. The number of apoptotic cells was investigated using 
TUNEL labeling. We also used active actCasp6, which is an enzyme involved in axonal 
degeneration and has been shown to be increased in disorders such as Alzheimer’s [294] and 
Huntington’s disease [295].  
At P21, a significantly increased number of apoptotic cells were found in several hypothalamic 
areas, such as Arc, VMH, LHA and DM, in the anx/anx compared to +/+ mice. Furthermore, 
at P21, we detected double-labeling of NPY and actCasp6 in Arc and DMH of anx/anx mice, 
further indicating degenerating NPY fibers. We could not see a clear detection of double-
labeling of actCasp6 and α-MSH in anx/anx mice. Double-labeling of actCasp6 and NPY, or 
actCasp6 and α-MSH was not detected in +/+ mice. 
Taken together, the results from Paper II, shows increased amounts of apoptotic cells and 
signs of degeneration of NPY fibers in the hypothalamus of the anx/anx mice. 
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4.4 DEFECTS IN THE OXPHOS SYSTEM IN THE ANX/ANX MOUSE (PAPER III 
& V) 
4.4.1 First signs of OXPHOS dysfunction in anx/anx mice 
In Paper III, a microarray analysis of the Arc from anx/anx and +/+ mice was performed. This 
analysis revealed 132 up regulated and 73 down regulated genes in anx/anx mice compared to 
+/+ mice, with ≥ 1.4-fold average increase or decrease. These genes with an altered expression 
level were included in an IPA analysis, to identify the top canonical pathways most likely to 
be involved in the phenotype of the anx/anx mouse. This resulted in several pathways centered 
around the OXPHOS system and mitochondrial dysfunction, as well as several genes related 
to mitochondrial function and oxidative stress (e.g. Sod1, Prdx1, Bcl211, and Cox5B). This was 
the first indication that the anx mutation could be involved in the mitochondrial OXPHOS 
system. 
4.4.2 The anx-mutation and gene  
In Paper III, we further investigated the anx-gene and searched for the anx-mutation, its 
biological function in, and relation to the phenotype of the anx/anx mouse. The anx gene has 
previously been localized to a 500-kb interval on mouse chromosome 2 [31]. Approximately 
40 genes are found in the anx-interval. The microarray analysis gave us an overall insight in 
the different pathways affected in the anx/anx mice. However, it also directed our interest to 
the Ndufaf1 gene that was among the down regulated genes found in the microarray. The 
Ndufaf1 gene is located within the anx-interval and was in fact one out of two of the 40 genes 
in the interval that were affected in the array data. Based on that and on its biological function, 
the Ndufaf1 gene became our number one anx-candidate gene. The downregulation of the 
Ndufaf1 gene seen in the microarray analysis was verified by Taqman real time expression 
analysis. This showed a downregulation in the Ndufaf1 gene in total brain, pancreas, liver and 
lung at mRNA level. However, no significant differences were found in kidney and heart, likely 
due to high variance in the sample set. Using a Western blot the downregulation of the Ndufaf1 
gene was also seen at protein level in total brain.  
In the search for the anx-mutation we sequenced the Ndufaf1 gene; however, no unique 
sequence alterations were found in coding sequences, neither in genomic DNA (exon) nor in 
cDNA. One explanation for this could be that the mutation could be located in a regulatory 
sequence such as a promotor region. This view is supported by the different expressions in 
various tissues.  
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When no unique sequence alterations were found, we continued by performing an allele-
specific analysis. This was done to make sure that the downregulation of Ndufaf1 was caused 
by the anx-mutation and was not due to a secondary effect, such as the starvation of the anx/anx 
mice. By the use of heterozygous (anx/+) mice, that carry one anx-allele and one wt-allele, the 
experiment could be carried out based on the fact that the anx/+ mice do not show decreased 
body weight or aberrant neurological phenotype. By comparison of genomic DNA and cDNA 
levels of the anx-allele and the wt-allele a ratio was given. A ratio (cDNA versus genomic 
DNA) of 1 indicates no differences in allelic expression, and a ratio above one indicates a 
higher expression of the wt-allele. The results from this experiment showed, in all four cases 
studied, a ratio above one, suggesting that the downregulation of Ndufaf1 expression levels in 
anx/anx mice is associated with the anx-allele of the Ndufaf1 gene and is not due to a secondary 
effect of the phenotype.  
4.4.3 Assembly and activity of hypothalamic OXPHOS CI in anx/anx mouse 
The next step was to investigate potential effects of the downregulated Ndufaf1 gene, i.e. the 
effect of the anx-mutation. The Ndufaf1 gene encodes a mitochondrial CI assembly factor in 
the OXPHOS system [201]. CI is the largest of the five OXPHOS complexes, consisting of 45 
different proteins. The role of Ndufaf1 is to, together with other CI assembly factors (Tab. 1), 
build up a properly assembled mitochondrial CI. If this fails, the functions of CI are affected, 
i.e. the oxidation of NADH and the transport of electrons, which in the end could result in 
leakage of electrons, increased production of ROS and reduced production of ATP.   
With the function of Ndufaf1 in mind, as well as the microarray results suggesting a 
hypothalamic mitochondrial dysfunction in the anx/anx mouse, the levels of fully and partly 
assembled CI in anx/anx and +/+ mice were analyzed using BN PAGE. This revealed lower 
levels of fully assembled CI, as well as the presence of sub-complexes of CI, in the anx/anx 
hypothalamus. 
Further, we analyzed the efficiency of the mitochondrial respiration in the hypothalamus of the 
anx/anx and +/+ mice using high-resolution respirometry. This analysis showed that the 
coupled respiration from hypothalamic CI is approximately 30% lower in anx/anx mice. The 
mitochondrial respiration via CII showed no significant difference comparing anx/anx and +/+ 
mice, indicating that the defects observed in the OXPHOS are specific for CI more and not a 
general defect of the respiratory chain. To exclude that the dysfunctions in the OXPHOS 
system in the anx/anx mice are due to a decrease in number of mitochondria, we performed a 
mitochondrial count. This showed that there is no difference in the number of mitochondria. 
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Thus, the aberrances in the OXPHOS system are not due to a decreased mitochondrial number 
in anx/anx mice.  
The mitochondrial dysfunction seen in Paper III was confirmed in Paper V by evaluating the 
enzymatic activity of the different complexes in the respiratory chain in isolated mitochondria 
from hypothalamus of anx/anx and +/+ mice. A small but significant decrease in CI activity 
and in CI + CIII activity was seen in anx/anx compared to wt hypothalamus. No differences 
were seen in CII or in CII + CIII or in CIV activity. By using the mitochondrial marker citrate 
synthase (CS), the levels of mitochondria between anx/anx and +/+ mice were compared. No 
difference in CS activity was seen, indicating a similar level of mitochondria in the two groups. 
This confirmed that the mitochondrial CI dysfunction in the anx/anx mouse cannot be 
explained by a difference in mitochondrial content.  
The results from Paper III and Paper V show a reduced efficiency of hypothalamic OXPHOS 
CI assembly and activity in the anx/anx mouse. 
4.4.4 Oxidative stress in the anx/anx hypothalamus 
The Affymetrix microarray study performed in Paper III revealed that several genes involved 
in oxidative stress are up regulated in the Arc in anx/anx mice, e.g. SOD1 and peroxiredoxin 
1. Markers for ROS and oxidative stress were also analyzed by histochemical methods. We 
used dihydroetidium injections, which create a red fluorescent staining in the tissue when 
reacting with endogenous ROS. We could see increased levels of ROS in the anx/anx 
hypothalamus. Furthermore, we detected increased levels of SOD2, a mitochondrial scavenger 
of ROS. This shows an increased oxidative stress in anx/anx hypothalamus, possibly as an 
effect of the decreased hypothalamic levels of fully assembled CI.  
The results from Paper III suggest that the phenotypes seen in the anx/anx mice, e.g. the 
anorexia and the hypothalamic neurodegeneration of appetite-regulating neurons, are 
associated with mitochondrial CI dysfunction that is related to an increase of ROS in the 
anx/anx hypothalamus.  
4.5 MITOCHONDRIAL DYSFUNCTION AND INFLAMMATION IN ENDOCRINE 
PANCREAS (PAPER IV) 
The hypothalamic inflammation reported in Paper I and II, and the hypothalamic 
mitochondrial dysfunction demonstrated in Paper III, led us to investigate whether the 
inflammation and OXPHOS dysfunction is also shown in endocrine pancreas in the anx/anx 
mouse.  
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4.5.1 Signs of mitochondrial dysfunction in anx/anx pancreatic islets 
In Paper IV we detected a strong downregulation of the Ndufaf1 gene in isolated islets from 
anx/anx mice. We therefore continued by studying the mitochondrial function in anx/anx islets. 
Using in-gel activity assay, we could detect a reduced mitochondrial CI activity in isolated 
anx/anx islets. To further analyze the mitochondrial function we measured the MMP when 
shifting from 3 to 11 mM glucose. MMP is related to the cells’ capacity to generate ATP by 
oxidative phosphorylation, and is therefore an important indicator of cells’ health or injury. We 
detected a 50% decreased MMP 3G/11G in anx/anx compared to wt isolated islets. The results 
from Paper IV suggest a mitochondrial dysfunction of anx/anx islets. 
4.5.2 Signs of inflammation in anx/anx pancreatic islets 
In Paper IV, we also investigated expression of inflammatory markers in anx/anx pancreatic 
islets and serum levels of FFAs. We studied inflammation with IHC analysis of intact pancreas 
and in isolated islets cultured overnight using antisera for Iba1 and F4/80, both markers for the 
macrophage lineage. We could detect a significantly increased macrophage infiltration in intact 
pancreas from anx/anx mice using double-labeling for Iba1 and insulin, indicating 
inflammation. However, in isolated islets cultured overnight no increased macrophage 
infiltration was seen. To establish the specificity of the experiment, we also carried out a 
double-labeling using Iba1 and F4/80 antiserum. This resulted in an almost complete overlap 
of the two markers. We continued by investigating the levels of free fatty acids in serum, and 
this revealed a 50% increase in free fatty acids in nonfasted anx/anx serum.  
We then concluded that the difference in results, i.e. the inflammation seen in intact pancreas 
and the absence of inflammatory markers detected in isolated islets, could be due to a higher 
concentration of free fatty acids in in anx/anx serum, since the isolated islets are cultured in the 
absence of free fatty acids.  
4.6 DISTURBED GLUCOSE HOMEOSTASIS AND INSULIN SECRETION IN 
THE ANX/ANX MOUSE (PAPER IV) 
In Paper IV, we studied whole body glucose homeostasis and pancreatic islet function in the 
anx/anx mouse, monitoring several features such as insulin secretion and changes in free 
cytosolic Ca2+ concentrations ([Ca2+]i). 
4.6.1 In vivo glucose tolerance test 
In Paper IV, we studied whole body glucose homeostasis in anx/anx mice. We performed an 
ip glucose tolerance test (ipGTT) with 5-h-fasted or nonfasted anx/anx and wt mice. Thus, we 
evaluated the blood glucose levels and the serum insulin levels immediately before ip 
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administration of glucose (0 min) and after 30, 60 and 90 minutes. The blood glucose 
concentration in fasted anx/anx mice was significantly lower before ipGTT but markedly 
elevated after 30 minutes. This was associated with significantly decreased insulin serum 
levels. The nonfasted anx/anx mice showed lower blood glucose levels before ipGTT 
compared to wt mice; however, as in the fasted mice, markedly elevated blood glucose levels 
were seen after ip injection of glucose. We could conclude that anx/anx mice show a marked 
glucose intolerance associated with reduced insulin release. 
We further investigated changes in β-cell mass, pancreatic hormone levels including total 
pancreatic insulin content and β-cell proliferation, to explain the disturbed glucose homeostasis 
in the anx/anx mouse. To study β-cell proliferation, double-labeling of insulin and Ki-67, a 
marker for proliferation, was carried out. This revealed an equal number of Ki-67-ir β-cells in 
anx/anx and wt pancreatic islets, i.e. no difference in β-cell proliferation was seen. We 
continued by investigating changes in β-cell mass by IHC. The amount of β-cells in anx/anx 
and wt islets was measured as the percentage of islet area occupied by insulin 
immunoreactivity, and did not differ between groups. Also, no significant differences were 
seen for the percentage of islet area occupied by glucagon or somatostatin. We analyzed 
pancreatic hormone levels by ELISA. Total glucagon content and total insulin content in 
anx/anx and wt pancreas normalized to total pancreatic protein did not show any significant 
difference. The lack of changes in β-cell mass, total pancreatic insulin content and β-cell 
proliferation suggests that the glucose intolerance and disturbed pancreatic islet insulin 
secretion cannot be explained by changes in these parameters. 
4.6.2 In vitro insulin secretion and impaired [Ca2+]i from anx/anx and wt islets 
What could then be the cause for the glucose intolerance and the reduced insulin secretion seen 
in vivo following an ipGTT? To further investigate the cause for this we performed 
experiments on isolated islets to examine the insulin content and insulin secretion in vitro.  
When measuring insulin content in isolated and cultured islets from anx/anx and wt mice we 
detected that anx/anx islets have a significantly reduced insulin content compared to wt islets 
after normalizing for protein content.  
We also evaluated dynamic and static insulin secretion in response to glucose or KCl 
stimulation in isolated islets. When studying the islets in the presence of 3 mM glucose, 
representing the basal value, insulin concentration was similar between anx/anx and wt. 
However, after addition of 11 mM glucose, islets from anx/anx mice showed significantly 
higher insulin release compared to wt islets. In addition, depolarizing the islets with 25 mM 
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KCl also resulted in an increased insulin secretion from anx/anx compared to wt islets. Both 
dynamic and static insulin secretion showed the same results. The conclusion was that, even 
though isolated and cultured islets from anx/anx mice show lower insulin content, the insulin 
secretion from these islets, when stimulated with high glucose or KCl levels, is significantly 
increased compared to wt. This indicates that the reduced insulin release in response to the 
ipGTT in the anx/anx mice is not a cause of a decreased capacity to secrete insulin.  
One important factor for a well-functioning insulin secretion is an adequate increase in free 
cytosolic Ca2+ concentrations ([Ca2+]i). We therefore continued by performing measurement of 
changes in [Ca2+]i, when islets from anx/anx and wt mice were stimulated with high glucose 
concentration, i.e. 11 mM or 25 mM KCl. Several differences showing an impaired [Ca2+]i 
handling in anx/anx islets were observed.  
When glucose concentration rises there are, during normal circumstances, an uptake of Ca2+ in 
the endoplasmic reticulum. In our experiment this can be observed as a first initial decrease in 
[Ca2+]i right after increasing the glucose concentration from 3 to 11 mM. The first defect 
observed in anx/anx islets was a complete suppression of this decrease, whereas the wt islets 
showed a normal first initial decrease in [Ca2+]i in all islets analyzed. After stimulating the islets 
with a high glucose concentration, the resulting increase in [Ca2+]i was significantly lower in 
anx/anx compared to wt islets. Furthermore, when changing the glucose concentration from 11 
mM to 3 mM, we detected a slower return of [Ca2+]i to its basal levels in anx/anx versus wt 
islets. No differences were seen in [Ca2+]i if stimulating the anx/anx islets with KCl, whereas 
KCl stimulation increased insulin release.  
In Paper IV, we find that, following an ip injection of glucose, the anx/anx mouse shows 
glucose intolerance and reduced insulin release. However, insulin release from isolated anx/anx 
islets is increased after stimulation with glucose or KCl. The reduced insulin release following 
an glucose ip injection in vivo was not paralleled by the similar results in vitro, since isolated 
islets stimulated with high glucose or KCl showed increased insulin release. Further, we 
detected elevated levels of circulating FFAs in anx/anx serum and inflammation in intact 
pancreas but not in isolated islets cultured in the absence of FFAs. The conclusion of Paper 
IV is that the special characteristics of the anx/anx endocrine pancreas are dependent on the 
increased serum FFA levels and on the accompanying inflammation which inhibits the insulin 
secretion in vivo.  
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4.7 REDUCED HYPOTHALAMIC METABOLISM IN THE ANX/ANX MOUSE 
(PAPER V) 
In Paper III we showed that mitochondrial CI in the OXPHOS system is dysfunctioning in the 
anx/anx mouse. This CI dysfunction is related to the aberrant expression of hypothalamic 
neuropeptides and transmitters regulating food intake. The anx/anx mouse shows an abnormal 
response to negative energy balance. In Paper V we further evaluated the reason for this 
abnormal response by investigating whether the anx/anx mouse shows a lower hypothalamic 
activity as a consequence of the dysfunctional CI. The hypothalamic activity, i.e. neuronal 
firing and transmitter release, is dependent of a well-functioning glucose utilization and energy 
metabolism. We therefore used these two processes to study neuronal activity. 
In Paper V, hypothalamic activity of several metabolites was studied using both enzymatic 
analyzes and HPLC. PCr, Cr, ATP, lactate and G6P were analyzed by enzymatic analyzes, and 
IMP, ADP, ATP and AMP by HPLC. All metabolites were analyzed in the basal state and after 
one minute of ischemia in anx/anx and wt hypothalamus. These values were also used to 
calculate the anaerobic ATP turnover to assess hypothalamic metabolism under a stress 
condition, in this case ischemia. Hypothalamic protein levels of AMPK and glucose 
transporters were also measured, and [3H]-2-deoxyglucose injections were made to evaluate 
hypothalamic glucose uptake.  
The results regarding metabolites showed that both in the basal state and after ischemia PCr 
was significantly higher and lactate was significantly lower in anx/anx compared to wt 
hypothalamus. In the basal state, we saw no difference in ATP levels; however, after one 
minute of ischemia ATP levels were significantly higher in anx/anx compared to wt 
hypothalamus. When comparing the basal state to the ischemic state, the one minute of 
ischemia resulted in depletion of ATP and PCr, and accumulation of lactate in both anx/anx 
and wt hypothalamus.  
To investigate the hypothalamic metabolism under a stress condition, i.e., in the ischemic 
hypothalamus, the anaerobic ATP turnover was calculated using the mean difference between 
ischemic and basal metabolite values assessed by HPLC, using the following formula: 
−2ΔATP − ΔPCr + (1.5Δ lactate). Under this condition, glycolysis (lactate accumulation) was 
reduced by almost 40%, whereas anaerobic ATP turnover was ~10% lower in the anx/anx 
group.  
During ischemia the AMP and IMP levels were decreased and the ATP levels were increased 
in the anx/anx hypothalamus. In addition, the ATP/AMP ratio was significantly increased in 
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anx/anx compared to wt hypothalamus. AMP and IMP are breakdown products of ATP, where 
IMP is a particularly sensitive indicator of net ATP degradation.  
Further investigations on protein expression of AMPK, AMPK-P and GLUTs revealed 
significantly elevated protein levels of AMPK-T and GLUT4 in anx/anx compared to wt 
hypothalamus. Further, the ratio of AMPK-P/AMPK-T was decreased in anx/anx 
hypothalamus indicating a lower degree of AMPK activation 
The rate of glucose uptake in the hypothalamus as well as in other brain areas, i.e. thalamus 
and motor cortex, as well as in the liver, was measured by injections with [3H]-2-deoxy-glucose 
in anx/anx and wt mouse. Prior to the analysis, the mice were fasted for 5-6 hours. Significantly 
lower glucose uptake was observed in the anx/anx hypothalamus and in all other brain areas 
studied, as well as in the liver.  
The results from Paper V, i.e. the reduced hypothalamic glucose uptake, the decreased 
activation state of AMPK, the reduced levels of AMP and IMP (breakdown products of ATP), 
and the increased levels of ATP and decreased levels of lactate after ischemia, all indicate a 
reduced hypothalamic metabolism, i.e. hypometabolism, in the anx/anx mouse both during 
basal and stress conditions. 
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5 CONCLUSIONS & HYPOTHESES 
This thesis, based on the anorectic anx/anx mouse model, has been focused on advancing our 
understanding of the mechanisms leading to the anorectic phenotype of this mouse. Its unique 
characteristics, i.e. the starvation and the premature death, have previously been linked to 
aberrances and degeneration of discrete hypothalamic neuron populations expressing certain 
neuropeptides and transmitters of importance for the control of appetite. The studies included 
in this thesis provide the first evidence that the underlying cause for the anorectic phenotype in 
the anx/anx mouse is related to a mutation in one of the five complexes (CI-V) of the 
mitochondrial OXPHOS. More specific, we provide evidence for a downregulation of the gene 
for the CI assembly factor Ndufaf1, resulting in lower levels of CI, accumulation of sub-
complexes, decreased CI activity and respiration and increased oxidative stress in the anx/anx 
mouse. We propose that this CI deficiency in the anx/anx hypothalamus may in fact represent 
a major contribution to the starvation of this mouse. We present evidence for this link between 
anorexia, CI dysfunction and increased levels of ROS in Paper III. A recent study further 
supports this link as it shows CI dysfunction and oxidative stress in leukocytes from patients 
with AN [197]. CI is the main producer of ROS even under normal conditions [170]. Results 
in Paper III indicate that a reduced capacity of CI can result in increased leakage of electrons 
from CI, producing even more ROS leading to oxidative stress. These results are interesting 
also because it is known that ROS has an additional role as signaling molecule, with direct 
effects on hypothalamic neurons and thereby regulating food intake; in fact, increased levels 
of ROS have been shown to inhibit food intake [167-169]. We therefore speculate that ROS at 
an early stage inhibits food intake in the anx/anx mouse. However, in the long run the increased 
levels of ROS can induce oxidative stress and inactivation and degeneration of certain Arc 
neurons in these mice [296, 297].  
We evaluated both the activation state (Paper V) as well as the possible degeneration of the 
Arc neurons (Paper I, II). Indeed, we detected several signs of a neurodegenerative process in 
the hypothalamus of the anx/anx mice. Even if the anx/anx mouse shows a normal development 
of the AgRP/NPY system until P12, the normal increase in fiber density will then start to 
decrease; and at P21 the immunoreactivity for AgRP is distinctly decreased in nerve terminals, 
and dramatically increased in cell bodies. This process overlaps both in time and space with 
the activation of microglia, and with increases of MHC class I mRNA and protein both in 
microglia and Arc neurons expressing Y1 or AgRP. We could also see that the POMC/CART 
neurons are reduced in anx/anx mice at P21. In addition, we detected increased number of 
apoptotic cells in the hypothalamus of anx/anx mice by using TUNEL-labeling, as well as 
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demonstrating co-labeling of NPY and actCasp6, a marker for axonal degeneration, in the Arc 
and several other hypothalamic brain areas. Taken together, these results strongly suggest a 
degenerative process in the anx/anx hypothalamus.   
Furthermore, our results in Paper II suggest that the activation state of Arc neurons is changed 
in the anx/anx mice. Several studies have shown that neurons are more likely to express MHC 
class I, when they are in a silent or in an inactive state, compared to active neurons [290, 298]. 
We detected that the anx/anx Arc NPY/AgRP and POMC/CART neurons expressing MHC 
class I have very low levels of Fos B, a marker for cellular activity, indicating a silenced or 
inactive state. This could be a consequence of the CI deficiency, and thus low ATP levels, with 
the aim to prevent cell death of these neurons. Another role for MHC class I molecules is to 
preserve synapses and to induce regeneration after injury [292]. Thus, the upregulated MHC 
class I molecules in the Arc neurons could protect these neurons from synaptic elimination. 
Indeed, hypothalamic activity is dependent on a well-functioning energy metabolism.  
In Paper V, we further evaluated the activation state of the anx/anx hypothalamus by 
investigating the metabolism in this brain region. The anx/anx hypothalamus showed a lower 
rate of glucose uptake, decreased lactate content and increased PCr content in the basal state. 
This reflects a low metabolic stress, hypometabolism and a lower neuronal activity. Similar 
changes have been reported in AD patients [299-301].  
Impaired oxidative phosphorylation has previously been linked to β-cell dysfunction and the 
development of diabetes [132, 257-261]. Also, in Paper III, we detected a downregulation of 
the Ndufaf1 gene not only in brain but also in pancreas. We therefore continued to study the 
function of the endocrine pancreas in the anx/anx mouse. The results from Paper IV gave us 
new and valuable insights in the association between anorexia, mitochondrial dysfunction, 
inflammation, glucose intolerance and β-cell dysfunction. Following an ipGTT the anx/anx 
mice showed glucose intolerance and reduced insulin secretion. We also detected elevated 
levels of FFA in anx/anx serum and increased macrophage infiltration and inflammation in 
anx/anx islets from intact pancreas. However, when isolated anx/anx islets were cultured in 
the absence of FFAs, insulin secretion was no longer reduced. In line with this, no macrophage 
infiltration was seen in isolated and cultured anx/anx islets. Macrophages have been shown to 
release proinflammatory cytokines, that are known to inhibit insulin secretion [302, 303]. 
Thus, the increased serum levels of FFAs and the macrophage infiltration and inflammation in 
islets from intact pancreas in the anx/anx mouse may be responsible for the decreased insulin 
secretion and inflammation seen in vivo. Further support for this hypothesis is seen in several 
studies that have related chronically increased levels of FFAs to both inflammation and 
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metabolic disorders. Increased levels of FFAs have been observed in both obesity, AN and in 
diabetes [258, 259, 304]. In obesity, the high levels of FFAs are due to the increased fat 
deposits and in AN it is due to an increased breakdown of the fat deposits [304-306]. 
Furthermore, elevated levels of FFAs can also inhibit glucose-induced insulin secretion and 
result in pancreatic inflammation and β-cell dysfunction [307, 308].  
In Paper IV we also report on changes in [Ca2+]i in response to high glucose concentrations. 
After stimulating the islets with high glucose concentration, the resulting increase in [Ca2+]i 
was significantly lower in anx/anx compared to wt islets. No differences were seen when 
[Ca2+]i was stimulated with KCl. Why do we see an alteration in [Ca2+]i in response to glucose 
and not in response to KCl?  A likely explanation is that KCl acts directly on the voltage-gated 
calcium channels, causing Ca2+ influx and insulin secretion. In contrast, glucose causes insulin 
secretion via uptake by GLUT2, increased ATP production, closure of the ATP-sensitive 
potassium channel, membrane depolarization and then opening of voltage-gated Ca2+ channels. 
This indicates that the cause for the decreased [Ca2+]i in response to glucose must lie upstream 
of the voltage-gated calcium channels. We suggest that the decreased CI activity and impaired 
change in MMP found in the anx/anx islets contribute to the impaired [Ca2+]i when changing 
the glucose concentration from low to high. Thus, Paper IV provides a link between anorexia, 
CI dysfunction and β-cell dysfunction. That goes in line with the fact that diabetic patients 
show an increased risk of developing an eating disorders, and that OXPHOS dysfunctions are 
linked to the development of diabetes [18, 19, 304-306, 309].  
The papers in this thesis show that the phenotypes of the anx/anx mouse so far are related 
mostly to the brain and the pancreas. In the brain, the aberrances and the neurodegeneration are 
specifically seen in the hypothalamus and likely not related to the whole brain, even though the 
downregulation of the Ndufaf1 mRNA and protein is seen in total brain. How come that the 
mutation in the Ndufaf1 gene and the subsequent CI dysfunction and oxidative stress only affect 
specific tissues and brain regions? An explanation could be that some factors make specific 
tissues and brain regions extra sensitive to CI deficiency and oxidative stress. One such factor 
of interest is a specific type of ATP-sensitive potassium channels (K+
-ATP) [310-312]. These 
channels consist of two types of subunits, the pore‐forming potassium channel (Kir6-) and the 
regulatory sulphonylurea receptor subunit (SUR) [313, 314]. This type of K+
-ATP channels have 
been shown to be extra sensitive to CI inhibition [314] and become activated by mitochondrial 
CI dysfunction, leading to reduced neuronal activity, i.e. lower neuronal firing. They are 
expressed by some hypothalamic neurons such as the POMC/CART and AgRP/NPY neurons, 
and by the dopaminergic neurons in the substantia nigra as well as by the pancreatic β-cells 
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[310-312, 315]. These channels are regulated by intracellular ATP so that high levels of 
intracellular ATP close the channel [316]. This also means that during times of ATP depletion, 
such as metabolic stress and ischemia, the K+
-ATP channels are open, resulting in reduced 
neuronal activity and neurotransmitter release, in order to save ATP [317]. This represents a 
neuroprotective role of the Kir6.2/SUR1 K+
-ATP channels [317]. However, during times of 
chronically reduced neuronal activity, the gene and protein expression important for neuronal 
survival will decrease, leading to neurodegeneration [318, 319]. Thus, short-term activation of 
the neuronal K+
-ATP channels can protect the neurons against metabolic stress, whereas a 
chronic activation of the K+
-ATP channels is dangerous to the cell. This goes in line with the 
findings in the anx/anx mouse, showing CI deficiency and reduced neuronal activity in 
hypothalamus: the CI deficiency could result in inactivation of the hypothalamic appetite 
regulating neurons expressing the Kir6.2/SUR1 K+‐ATP channels, and in the longer 
perspective degeneration of these neurons.   
In conclusion, the results from this thesis suggest that the anorexia and disturbed feeding 
behavior in the anx/anx mouse as well as the hypothalamic neurodegeneration of appetite 
controlling neurons in the Arc of the anx/anx mouse are related to a mitochondrial CI 
dysfunction, caused by a downregulation of the CI assembly factor Ndufaf1 gene. Both 
neurodegeneration and poor feeding in infants are attributes commonly seen in humans with 
disorders caused by OXPHOS CI dysfunctions. Furthermore, the anx/anx mouse shows 
glucose intolerance, disturbed insulin secretion and pancreatic β-cell dysfunction that are 
related to mitochondrial dysfunction, increased FFA in serum and inflammation in islets. Both 
inflammation and impaired oxidative phosphorylation have previously been linked to β-cell 
dysfunction and the development of diabetes [132, 257-261]. Increased levels of circulation 
FFA, which are involved in the generation of inflammation [258, 259], are seen both in diabetic 
and obese, as well as in AN patient [304-306, 309]. Furthermore, a group with increased risk 
of developing AN is patients suffering from diabetes [18, 19, 23]. Several of the phenotypes 
observed in the anx/anx mouse are also seen in AN patient. These include, self-starvation, 
mitochondrial dysfunction and increased levels of FFA. Taken together, the results from this 
thesis work, when seen against the background of a spectrum of human disorders, show the 
value of the anx/anx mouse to gain a better understanding of conditions involving a 
dysregulated appetite. Perhaps, in the long run, they may even lead to new therapeutic 
methods of such conditions. 
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6 FUTURE PERSPECTIVES 
As discussed earlier in this thesis, the best treatment methods for AN still need to be found. As 
for today, the most important factor for full recovery is early treatment and nutrient restoration. 
This thesis provides a link between anorexia and CI dysfunction. When it comes to CI 
deficiencies, there is currently no cure and the therapeutic strategies can relive symptoms but 
are unable to cure or even delay the progress of the disease.  
There are several aspects of the anorectic biology of the anx/anx mouse that need to be studied. 
The role of metabolic alterations relating to fatty acids should be investigated further as it seems 
to play a critical role in the pancreas. Transgenic models may be used to rescue the phenotype, 
perhaps involving overexpression of specific components of CI or overexpression of the 
Ndufaf1 gene. 
The correlation between anorexia, mitochondrial deficiency and CI dysfunction found in the 
studies in this thesis helped us come one step closer to a better understanding of mechanisms 
underlying the development of anorectic behavior. Thereby better therapeutic treatment 
methods may emerge that could lead to improvement and perhaps even recovery from various 
kinds of eating disorders. Is it possible to define a subgroup of patients with anorexia with a 
clearcut loss of hypothalamic neurons? Would it be possible to intervene more aggressively in 
this group to avoid cell death? There are already survival promoting factors used in clinical 
trials in other neurological conditions involving excessive cell death. Could some of these be 
used or could it be that prevention is more critical with intensive nutritional intervention early 
in the disease? This would require development of biomarkers that can be applied as a 
screening tool very early or even before disease onset in at risk individuals. 
A recent study done by Victor et. al. [197] showed CI dysfunction and oxidative stress in 
leukocytes from AN patient. To control that this CI dysfunction and oxidative stress is not due 
to a secondary effect caused by the starvation but rather a part of the underlying biology causing 
this behavior, one could further investigate these components in healthy individuals previously 
struggling with AN.  
A future step would be in a curable manner, taking a mitochondrial approach to find new 
treatment methods for different kinds of eating disorders, and as a first step to cure the anx/anx 
mouse. Several approaches could be taken, for example, to treat the anx/anx mice with anti-
inflammatory and anti-oxidative compounds. This could also be taken to the clinic, as a 
complement to the already existing treatment, one could enhance the AN treatment with anti-
inflammatory and anti-oxidative compounds. One could also try to improve the activity of CI 
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by treatment with riboflavin, as seen in patients with mutation in the CI assembly factor. This 
treatment resulted in increased CI activity and improved the clinical outcome of these patients 
[229]. This would require well controlled randomized controlled trials, most likely combined 
with a biomarker approach to a priori identify patients with an increase in oxidative stress or 
less active C1 in the hypothalamus. Whereas imaging techniques may be one avenue towards 
identifying this potential subgroup of patients, it may in fact detect individuals only after 
damage to neurons in the hypothalamus has occurred. Imaging research may therefore have to 
be combined with biochemical or molecular strategies to identify trait markers. This approach 
would be a way of introducing individualized medicine into the field of eating disorders. 
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